

ORLANDO, FL
FEBRUARY 15-17, 2024

10 Years
NRG
ONCOLOGY

2024 WINTER MEETING

NRG ONCOLOGY
2024 WINTER MEETING
Program Book

#NRG2024

Table of Contents

- 3 Welcome Message
- 4 NRG Mission Statement
- 5 Continuing Education Information
- 6 Approved CME Session Credit List
- 7 Social Media and WiFi Information
- 8 Meeting App Information
- 9 Hotel Map - *Orlando World Center Marriott*
- 11 Meeting Agenda

SESSIONS/SPECIAL EVENTS

- 16 Symposium - *"IDEA: Inclusion, Diversity, Equity, and Access of Underrepresented Patients to Clinical Trials"*
- 18 PSC Intro to Clinical Trials: Principles of NRG Oncology Clinical Trial Management for Nurse/CRPs
- 22 PSC Nurse/CRP Continuing Education Sessions
- 25 Pathology Committee
- 27 Early Career & New Investigator Educational Session
- 29 Translational Science Committee: *"The Role of Spatial Biology in Oncology: Opportunities & Challenges for Translational Research"*
- 31 General Session
- 33 Scientific Session
- 36 NCORP Town Hall
- 38 NRG-CC005 FORTE Workshop
- 40 Social Media Workshop Recording Info

WORKSHOP AGENDAS (CME/Non-CME)

- 43 Brain Committee General Meeting
- 44 Breast Cancer Workshop
- 45 Canadian Subcommittee Meeting
- 46 Cancer Care Delivery Research Committee
- 47 Cancer Prevention Control Committee
- 49 Cervix Cancer Subcommittee
- 52 Developmental Therapeutics Committee
- 56 DT Radiation Therapy Subcommittee
- 57 Gastrointestinal (GI) Cancer Committee Workshop
- 59 GI Colorectal Cancer Subcommittee
- 60 Genitourinary Cancer Workshop
- 62 Gynecologic Cancer Committee
- 67 Head and Neck Workshop
- 69 Immunotherapy Subcommittee
- 70 International Members Subcommittee Meeting
- 71 Lung Committee General Session
- 72 Medical Oncology Committee
- 73 NRG-BR008 Workshop
- 74 NRG-BR009 Workshop


- 75 NRG-CC011 Workshop
- 76 NRG-CC012CD Workshop
- 77 NRG Medical Physics Subcommittee (Virtual)
- 79 NRG Health Disparities Committee
- 80 NRG Oncology Imaging Committee
- 81 NRG Oncology Radiation Oncology GYN WG
- 82 NRG Radiation Oncology Committee
- 83 NRG Translational Science Breast Cancer WG
- 84 Ovarian Workshop
- 88 Particle Therapy Working Group
- 89 Patient Centered Outcomes Research (PCOR) Workshop
- 90 Pharmacy Subcommittee
- 91 Rare Tumor Subcommittee
- 92 Sarcoma Working Group
- 93 Translational Science Brain Cancer WG
- 94 Translational Science GYN
- 95 Translational Science Head & Neck Cancer
- 96 Translational Science Lung Cancer
- 97 Uterine Corpus Cancer Subcommittee

INSTITUTIONAL ACCRUAL

- 99 Member Accrual

ACKNOWLEDGEMENTS

- 106 Sponsors/Exhibitors
- 108 GSK Platinum Sponsor Advertisement
- 109 Immunogen Platinum Sponsor Advertisement
- 110 Commercial Supporters of Independent Medical Educational
- 111 Future Meeting Dates and Locations





Welcome to Orlando

The Winter 2024 NRG Oncology Semiannual Meeting

Thank you to our members and partners who have traveled near or far to join us in Orlando for the Winter 2024 NRG Meeting! We continue to honor our 10 years of innovations and impacts on cancer care as we work toward our NCI grant renewal.

Our Meeting features numerous sessions for every audience: physicians, research staff, new investigators, clinical research professionals, basic researchers, medical physicists, patient advocates, and more. The NRG General Session on Friday, February 16th from 12:00-1:00pm ET is a popular event relevant to all audiences. During the General Session, our NRG leadership will update attendees on the current and future organizational priorities, the ongoing efforts of our committees, and our top accruing sites. The NRG Scientific Session will be held on Friday afternoon from 3:00-4:00pm ET, where we will review recent major research results from NRG studies.

Do not forget to join us for the NRG Reception on Friday night, February 16th from 6:00-8:00pm. We invite our attendees to network and mingle among friends and colleagues while enjoying some refreshments.

As with every NRG Meeting, we hope that our attendees thoroughly engage in all sessions by exchanging ideas, asking questions, and providing feedback. All of your contributions during our NRG Meetings help us gather the momentum to fuel the many great initiatives that NRG seeks to accomplish throughout the year.

Please browse the full meeting agenda in our Program Book to explore all the potential sessions you can participate in.



We hope you have a successful and exciting NRG Meeting experience.



Quynh-Thu Le, MD
NRG Oncology Group Chair



Robert Mannel, MD
NRG Oncology Group Chair



Norman Wolmark, MD
NRG Oncology Group Chair





Advancing Research. Improving Lives.™

NRG Oncology Mission Statement

NRG Oncology seeks to improve the lives of cancer patients by conducting practice-changing multi-institutional clinical and translational research with emphases on gender-specific malignancies including gynecologic, breast, and prostate cancers and on localized or locally advanced cancers of all types.

For the Educational Objectives, we list the following:

- Inform the participants of the current state of clinical and basic oncologic research, particularly, but not exclusively as it relates to clinical trials.
- Provide participants with peer review critiques of progress (or lack of it) with the objective of self-improvement.
- Provide an opportunity to learn research administration and financial management in a cooperative group setting.
- Provide a forum for experts from diverse fields to improve research practices and patient management.

www.nrgoncology.org

#NRG2024



CONTINUING EDUCATION

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of The GOG Foundation, Inc. and NRG Oncology.

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of **28** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The GOG Foundation Inc. Continuing Education (CME) Program Mission Statement

The purpose of The GOG Foundation, Inc. CE program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

Disclosure Declaration

In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.



HOW DO I COLLECT CME/CEU CERTIFICATES?



CME Overall Meeting Certificates

- Scan the QR code above to begin:
- Complete the Overall Evaluation questions.
- Enter the Credits being claimed.
- Click Submit, your certificate will automatically be emailed to you.

Winter Symposium Evaluations

- Symposium Evaluation links will be emailed to all registered attendees.

CME Evaluations must be submitted by: March 4, 2024

CEU Certificates for PSC Sessions

- PSC CEU Evaluation links will be emailed to all registered attendees.

Questions?

CMEs: If you have issues accessing your certificate or questions about CME's please contact: cmeinfo@gog.org

CEUs: For questions about CEU's please contact: meeting-reg@NRGOncology.org

For questions or comments about this CME activity, please contact:
Michelle N. Small, MHA, Dir of Education Programs/CME Compliance at smallm@nrgoncology.org

CME Credit Listing

The following sessions/workshops have been approved to receive CME credits
for the meeting February 12-17, 2024.

Maximum credits up to **28.0** AMA PRA Category 1 Credits™

Monday, February 12, 2024		Approved Credits	Credits Claimed
11:00 am – 1:00 pm	Medical Oncology Committee	2.00	
3:00 pm – 4:30 pm	Developmental Therapeutics-Radiation Oncology Subcommittee	1.50	
4:00 pm – 5:00 pm	Social Media Workshop	1.00	

Tuesday, February 13, 2024		Approved Credits	Credits Claimed
11:00 am – 12:30 pm	Pharmacy Subcommittee	1.50	

Thursday, February 15, 2024		Approved Credits	Credits Claimed
7:30 am – 12:05 pm	PSCN/CRP - Introduction to Clinical Trials: Principles of Clinical Trial Management	4.00	
8:00 am – 12:00 pm	Winter Symposium - <i>"IDEA: Inclusion, Diversity, Equity and Access of Underrepresented Patients to Clinical Trials"</i>	4.00	
10:00 am – 11:00 am	Canadian Members Subcommittee	1.00	
11:30 am – 1:00 pm	Cancer Care Delivery Research Committee (CCDR)	1.50	
12:30 pm – 2:30 pm	Developmental Therapeutics Committee	2.00	
1:00 pm – 2:30 pm	Cancer Prevention and Control Committee (CPC)	1.50	
1:00 pm – 3:00 pm	Pathology Committee	2.00	
1:30 pm – 4:30pm	PSC/CRP - Introduction to Clinical Trials: Afternoon Discussion Sessions	3.00	
2:00 pm – 4:00 pm	Rare Tumor Subcommittee	2.00	
3:00 pm – 5:00 pm	Translational Science Committee	2.00	
4:00 pm – 6:00 pm	Patient Centered Outcomes Research (PCOR)	2.00	

Friday, February 16, 2024		Approved Credits	Credits Claimed
7:30 am – 11:45 am	PSCN/CRP Continuing Education Session	3.50	
8:00 am – 10:00 am	Cervix/Vulvar Cancer Subcommittee	2.00	
8:30 am – 10:00 am	NRG-CC011 Workshop	1.50	
10:00 am – 11:30 am	NCORP Townhall	1.50	
10:00 am – 12:00 pm	Uterine Corpus Cancer Subcommittee	2.00	
1:00 pm – 3:00 pm	Ovarian Cancer Subcommittee	2.00	
2:00 pm – 3:00 pm	NRG-CC012CD Workshop	1.00	
3:00 pm – 4:30 pm	Scientific Session	1.50	
4:30pm – 6:00 pm	Translational Science GYN Workshop	1.50	

Saturday, February 17, 2024		Approved Credits	Credits Claimed
7:30 am – 9:00 am	Genitourinary Cancer General Committee	1.50	
9:45 am – 11:45 am	Breast Cancer General Committee	2.00	

Note: This is for personal use to assist while completing the evaluation.

NRG2024 AT YOUR FINGER TIPS



FIND US ON SOCIAL MEDIA



Twitter / X
@NRGOnc



Facebook
@NRG
Oncology



Instagram
@NRGOnc



LinkedIn
@NRG
Oncology



YouTube
@NRGOnc

Use the hashtag **#NRG2024** to join the conversation.



CONNECT TO WIFI

Network Login: **nrgmeeting**

Passcode: **n1r2g345**

CHECK OUT OUR MEETING WEBPAGES

The NRG2024 main agenda, session flyers, attendee information, and more are posted on our NRG2024 webpages located at www.nrgoncology.org/Winter-Meeting-2024

Continue to check these pages after NRG2024 ends as we will update this section with any available presentation slides and recordings.



DOWNLOAD THE MEETING APP

- 1 Go to the Apple Store or Google Store
- 2 Download the CVENT Events App
- 3 Select CVENT EVENTS
- 4 Search for Event = NRG
- 5 Select: "NRG Oncology Winter 2024 Meeting"
- 6 Event ID = NRG ONCW24
(Please note there is a space after NRG)

Once you are in the NRG Oncology Winter Meeting, enter your first name, last name, and the email that you used to register for the event.


You'll receive a 6-digit verification code to your email. Enter the code on the screen. Tap the arrow.

Opt in to receive push notifications so you don't miss any important information!




Go to the Apple or Google Store and download the CVENT Event App.

MAIN CONVENTION CENTER
SINGLE-LEVEL MEETING SPACE WITH EXPANSIVE FOYER SPACE



ORLANDO WORLD CENTER MARRIOTT

HALL OF CITIES



HALL OF CITIES	DIMENSIONS		CAPACITY							
	LxWxH	SQ FT	Theatre	Classroom	Conference	Hollow Square	U-Shape	Reception	Rounds 10	Rounds 12
ANAHEIM/ATLANTA/BOSTON (COMBINED)	37x85x8	2,879	275	150	72	77	86	205	190	204
ANAHEIM	31x37x8	1,104	100	62	30	32	40	75	70	84
ANAHEIM/ATLANTA (COMBINED)	37x58x8	1,989	172	100	46	51	60	140	130	144
ATLANTA/BOSTON (COMBINED)	34x53x8	1,763	155	82	40	45	54	130	120	144
ATLANTA/BOSTON (EACH)	26x34x8	884	80	50	26	30	36	60	50	60
CHICAGO/DENVER (COMBINED)	32x53x8	1,562	135	85	45	46	54	110	110	120
CHICAGO/DENVER (EACH)	26x32x8	781	65	40	24	26	32	50	50	60
LOS ANGELES	26x38x8	927	80	50	30	30	36	75	60	72
MIAMI	37x37x8	1,310	125	80	34	40	48	100	80	96
NEW ORLEANS/NEW YORK (COMBINED)	43x53x8	2,017	190	120	44	48	60	150	130	156
NEW ORLEANS/NEW YORK (EACH)	26x43x8	1,015	95	60	36	32	38	75	60	72
SAN ANTONIO/SAN FRANCISCO (EACH)	25x32x8	836	60	40	20	24	30	55	50	48
ST. LOUIS/TAMPA (EACH)	26x34x8	810	70	40	25	26	32	60	50	60
WASHINGTON	25x34x8	878	70	40	25	26	32	60	50	60
EMERALD/DIAMOND/JADE (EACH)*	19x40x8	675	50	33	30	32	34	40	50	60
EMERALD EAST & SOUTH/ DIAMOND EAST & SOUTH/ JADE EAST & SOUTH (EACH)*	24x23x8	552		16	16		16			

*Located on Floors 4-6 of the East Tower



Advancing Research. Improving Lives.™

NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Orlando World Center Marriott
Orlando, FL
February 15-17, 2024 (All Sessions Eastern Time)

Monday, February 12, 2024		
11:00 am – 1:00 pm	Medical Oncology Committee	Virtual Only
1:30 pm – 3:00 pm	Imaging Committee Meeting	Virtual Only
3:00 pm – 3:30 pm	Joint Imaging & Medical Physics Seminar - Funding for Integrated Imaging/Biomarker Investigations	Virtual Only
3:30 pm – 5:00 pm	Medical Physics Subcommittee Meeting	Virtual Only
3:00 pm – 4:30 pm	Developmental Therapeutics-Radiation Oncology Subcommittee	Virtual Only
4:00 pm – 5:00 pm	Social Media Workshop	Virtual Only
Tuesday, February 13, 2024		
11:00 am – 12:30 pm	Pharmacy Subcommittee	Virtual Only
3:00 pm – 4:00 pm	Immunotherapy Subcommittee Meeting	Virtual Only
Thursday, February 15, 2024		
6:30 am – 7:30 am	Introduction to Clinical Trials Breakfast	Palms Foyer
6:30 am – 8:00 am	Symposium Breakfast	Sabal
7:00 am – 6:00 pm	Exhibits	Convention Center Entrance
7:00 am – 6:00 pm	Registration/Information Desk	Palms Registration Desk
2:00 pm – 4:00 pm	General Coffee Break	Palms Foyer
7:30 am – 12:05 pm	Protocol Support Committee Nurse/CRP Introduction to Clinical Trials: Principles of Clinical Trial Management	Webinar / Canary
8:00 am – 9:00 am	NRG QA Subcommittee (Closed)	Diamond Suite, 5 th Fl
8:00 am – 12:00 pm	Winter Symposium – "IDEA: Inclusion, Diversity, Equity and Access of Underrepresented Patients to Clinical Trials"	Webinar / Sabal
9:00 am – 10:00 am	International Members Subcommittee Meeting	Virtual / Magnolia 4 – 6
9:30 am – 10:30 am	NRG SDMC Executive Committee Meeting (Closed)	Boston
10:00 am – 11:00 am	Canadian Members Subcommittee Meeting	Virtual / Magnolia 4 – 6
11:30 am – 1:00 pm	Cancer Care Delivery Research Committee	Royal
11:30 am – 1:00 pm	Publications Committee (Closed)	Jade Suite, 6 th Fl
12:30 pm – 2:30 pm	Developmental Therapeutics Committee	Sago
1:00 pm – 2:30 pm	Cancer Prevention and Control Committee	Royal
1:00 pm – 2:30 pm	Membership Committee Meeting (Closed)	Emerald Suite, 4 th Fl

Revised 02/14/2024

All sessions will be in-person unless noted.



Advancing Research. Improving Lives.™

NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Orlando World Center Marriott
Orlando, FL

February 15-17, 2024 (All Sessions Eastern Time)

Thursday, February 15, 2024		
1:00 pm – 3:00 pm	Pathology Committee	Crystal A – C
1:30 pm – 2:00 pm	Pope Consulting Executive Summary Presentation	Magnolia 1 – 3
1:30 pm – 4:30 pm	Protocol Support Committee Nurse/CRP Introduction to Clinical Trials: Discussion Sessions	Webinar / Magnolia 7 – 10
2:00 pm – 2:30 pm	Diversity, Equity, and Inclusion Committee (Closed)	Magnolia 1 – 3
2:00 pm – 4:00 pm	Rare Tumor Subcommittee	Crystal H
2:30 pm – 4:00 pm	Early Career and New Investigator Educational Session	Magnolia 13 – 15
2:30 pm – 4:00 pm	Health Disparities Committee Meeting	Crystal G1
3:00 pm – 5:00 pm	Ancillary Projects Committee (Closed)	Anaheim
3:00 pm – 5:00 pm	Translational Science Committee – “The Role of Spatial Biology in Oncology: Opportunities & Challenges for Translational Research”	Canary
4:00 pm – 5:00 pm	Early Career and New Investigator Networking Session	Magnolia 16 – 18
4:00 pm – 5:00 pm	Washington University Endometrial SPORE Meeting (Closed)	Boston
4:00 pm – 6:00 pm	Imaging and Radiation Oncology Core (IROC) QA Centers Meeting (Closed)	Washington
4:00 pm – 6:00 pm	Patient Centered Outcomes Research (PCOR) Committee	Magnolia 20 – 21
5:00 pm – 6:30 pm	PSC Education & Training Subcommittee (Closed)	St. Louis
5:00 pm – 6:30 pm	PSC Mentorship Subcommittee (Closed)	Tampa
5:00 pm – 6:30 pm	PSC Protocol Review Subcommittee (Closed)	Jade Suite, 6 th Fl
5:00 pm – 6:30 pm	PSC Quality Control & Communications Subcommittee (Closed)	Diamond Suite, 5 th Fl
5:00 pm – 7:00 pm	Committee Chairs Dinner (Closed)	Magnolia 1 – 3
5:30 pm – 6:30 pm	Radiation Oncology GYN Working Group	Magnolia 13 – 15
5:30 pm – 8:30 pm	Patient Advocates Committee Meeting (Invitation Only)	Virtual / Magnolia 4 – 6

NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Orlando World Center Marriott

Orlando, FL

February 15-17, 2024 (All Sessions Eastern Time)

Friday, February 16, 2024

6:30 am – 8:30 am	Continental Breakfast	Palms Foyer
7:00 am – 5:00 pm	Exhibits	Convention Center Entrance
7:00 am – 5:30 pm	Registration/Information Desk	Palms Registration Desk
10:00 am – 12:00 pm	General Coffee Break	Palms Foyer
3:00 pm – 5:00 pm	General Coffee Break	Palms Foyer
6:30 am – 8:00 am	Protocol 210 Working Group <i>(Closed)</i>	Emerald Suite, 4 th Fl
7:00 am – 8:00 am	Voting Members PI Breakfast <i>(Closed)</i>	Magnolia 16 – 18
7:30 am – 10:00 am	Brain Tumor Core Committee <i>(Closed)</i>	Crystal H
7:30 am – 11:45 am	Protocol Support Committee Nurse/CRP- Continuing Education Session	Webinar / Canary
8:00 am – 9:00 am	Breast Cancer Rare Tumor Working Group	Magnolia 4 – 6
8:00 am – 10:00 am	Cervix/Vulva Cancer Subcommittee	Sago
8:00 am – 10:00 am	Head & Neck Surgical Working Group	Crystal G1
8:00 am – 10:00 am	Radiation Oncology Committee	Royal
8:30 am – 10:00 am	NRG-CC011 Workshop	Crystal J1
10:00 am – 11:30 am	NCORP Townhall	Crystal G1
10:00 am – 12:00 pm	Head & Neck Core Committee <i>(Closed)</i>	Magnolia 1 – 3
10:00 am – 12:00 pm	Hematologic Malignancy Working Group	Crystal DE
10:00 am – 12:00 pm	Sarcoma Working Group	Magnolia 7
10:00 am – 12:00 pm	Translational Science Breast Cancer Working Group <i>(Closed)</i>	Magnolia 4 – 6
10:00 am – 12:00 pm	Translational Science Lung Cancer Working Group	Crystal J1
10:00 am – 12:00 pm	Uterine Corpus Cancer Subcommittee	Sago
10:15 am – 11:45 am	Neurosurgical Working Group	Crystal A – C
10:15 am – 11:45 am	Particle Working Group	Royal
11:00 am – 12:00 pm	Local Regional Breast Cancer Subcommittee	Magnolia 8
12:00 pm – 1:00 pm	General Session	Sabal
1:00 pm – 2:00 pm	Head & Neck Health Equity Working Group <i>(Closed)</i>	Emerald Suite, 4 th Fl
1:00 pm – 2:00 pm	Head & Neck Patient-Reported Outcomes/Cost Effectiveness Working Group <i>(Closed)</i>	Jade Suite, 6 th Fl
1:00 pm – 2:00 pm	Head & Neck Previously Untreated Locoregionally Advanced Working Group <i>(Closed)</i>	Boston
1:00 pm – 2:00 pm	Head & Neck Recurrent/Metastatic Working Group <i>(Closed)</i>	Los Angeles
1:00 pm – 2:00 pm	Head & Neck Skin Working Group <i>(Closed)</i>	Anaheim
1:00 pm – 2:00 pm	Head & Neck Surgical QA Working Group <i>(Closed)</i>	Crystal DE
1:00 pm – 3:00 pm	Breast Cancer Core Committee <i>(Closed)</i>	Magnolia 11 – 12
1:00 pm – 3:00 pm	Genitourinary Cancer Core Committee <i>(Closed)</i>	Magnolia 1 – 3
1:00 pm – 3:00 pm	Lung Cancer Core Committee <i>(Closed)</i>	Crystal A – C
1:00 pm – 3:00 pm	Ovarian Cancer Subcommittee	Sago
1:15 pm – 2:30 pm	FORTE Workshop	Crystal G1
1:15 pm – 2:45 pm	Brain Tumor Committee General Session	Crystal H



Advancing Research. Improving Lives.™

NRG ONCOLOGY SEMIANNUAL MEETING FINAL AGENDA

Orlando World Center Marriott
Orlando, FL

February 15-17, 2024 (All Sessions Eastern Time)

Friday, February 16, 2024


2:00 pm – 3:00 pm	Health Disparities Committee SIG Leadership Meeting <i>(Closed)</i>	Diamond Suite, 5 th Fl
2:00 pm – 3:00 pm	NRG-CC012CD Workshop	Magnolia 7
2:00 pm – 3:00 pm	Translational Science Head & Neck Cancer Working Group	Crystal J1
3:00 pm – 4:30 pm	Scientific Session	Sabal
4:30 pm – 5:15 pm	NRG GI007 Study Update Session <i>(Closed)</i>	Boston
4:30 pm – 5:30 pm	NRG BR009 Workshop	Magnolia 7
4:30 pm – 6:00 pm	Head & Neck Cancer General Committee	Royal
4:30 pm – 6:00 pm	PSC CRP (CTN/CRA) Core Committee <i>(Closed)</i>	Magnolia 1 – 3
4:30 pm – 6:00 pm	Translational Science GU Cancer Working Group	Crystal J1
4:30 pm – 6:00 pm	Translational Science GYN Cancer Working Group	Virtual Only
5:00 pm – 7:00 pm	Korean Gynecologic Oncology Group	Crystal A – C
6:00 pm – 8:00 pm	NRG Oncology Reception	Sabal

Saturday, February 17, 2024

6:30 am – 10:00 am	Continental Breakfast	Palms Foyer
7:00 am – 12:30 pm	Exhibits	Convention Center Entrance
7:00 am – 12:30 pm	Registration/Information Desk	Palms Registration Desk
6:30 am – 8:00 am	Surgical Oncology Committee	Crystal H
7:00 am – 9:30 am	PSC Executive Session <i>(Closed)</i>	Diamond Suite, 5 th Fl
7:30 am – 9:00 am	Gastrointestinal Colorectal Cancer Core Committee <i>(Closed)</i>	Magnolia 4 – 6
7:30 am – 9:00 am	Genitourinary Cancer General Committee	Crystal G1
7:30 am – 9:00 am	Protocol Operations Management Committee <i>(Closed)</i>	Jade Suite, 6 th Fl
7:45 am – 9:30 am	Gynecologic Cancer Committee	Sago
8:00 am – 9:30 am	NRG-BR008 Workshop	Royal
9:15 am – 10:45 am	Gastrointestinal Non-Colorectal Cancer Core Committee Meeting <i>(Closed)</i>	Magnolia 4 – 6
9:15 am – 11:00 am	Lung Cancer General Committee	Crystal G1
9:45 am – 11:45 am	Breast Cancer General Committee	Royal
10:00 am – 12:00 pm	Translational Science Brain Cancer Working Group	Crystal J1
11:00 am – 12:30 pm	Gastrointestinal Cancer General Committee	Magnolia 13 – 15

Revised 02/14/2024

All sessions will be in-person unless noted.



10 Years
NRG
ONCOLOGY
2024 WINTER MEETING

NRG Oncology

Special Events, Sessions,
and Workshops



Winter Symposium

IDEA: Inclusion, Diversity, Equity and Access of Underrepresented Patients to Clinical Trials

Thursday, Feb 15, 2024 – 8 am to 12 pm - Eastern
NRG Oncology 2024 Winter Meeting
Orlando World Center Marriott, Orlando, FL

Program Chair: Bhavana Pothuri, MD, MS - Co-Chair: Jeffrey Hines, MD

Program Description

The Winter 2024 Educational Symposium includes noted Oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, Patient Advocates and others engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, Clinical Research Coordinators (CRC) and other interested Allied Health professionals.

The speakers will focus their presentations on providing a framework for the barriers and solutions to increasing IDEA (Inclusion, Diversity, Equity, and Access) of underrepresented patients to clinical trials.

Continuing Education

Accreditation Statement The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™ The GOG Foundation, Inc. designates this live internet activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evaluation Participants who complete the educational activity, evaluation and attendance verification will receive a certificate of

Learning Objectives

Following this activity, participants will be better able to:

- Recognize barriers underrepresented patients encounter with clinical trial participation
- Identify physician and care team related barriers to clinical trial opportunities for diverse patients
- Explain institutional barriers to clinical trial access
- Distinguish ways in which advocacy at the local, community, and national level can be leveraged to improve IDEA
- Identify protocol design and implementation barriers to clinical trial accrual of underrepresented patients

Winter 2024 Symposium Agenda

IDEA: Inclusion, Diversity, Equity and Access of Underrepresented Patients to Clinical Trials

Thurs, February 15, 2024 – 8 am to 12 pm ET – Orlando World Center Marriott, Orlando, FL

Program Chair: Bhavana Pothuri, MD, MS - Co-Chair: Jeffrey Hines, MD

Time	Topic/Title	Speaker/Moderator
6:30 am	Breakfast Buffet	
8:00 am	Welcome/Opening Remarks	Bhavana Pothuri, MD, MS Jeffrey Hines, MD
8:10 am	Session 1 – Physician and Patient Barriers to IDEA for Underrepresented People	Moderators: Angeles Alvarez Secord, MD Michelle Lightfoot, MD
8:10 - 8:25am	Physician Barriers: What can you do- “Just Ask”!	Nadine Barrett, PhD
8:25 - 8:45am	Breakout 1: Case Black woman- “She’s never going to comply, so I’m not going to bother discussing trial” (implicit bias, othering).	
8:45 - 9:00am	Patient Barriers: Let’s educate and address social determinants of health.	Tashanna Myers, MD
9:00 - 9:20am	Breakout 2: Young Hispanic patient wants to participate in cvx ca trial but is concerned about food insecurity, and transportation.	
9:20 - 9:35am	Q/A	
9:35 am	Session 2- Addressing Institutional Barriers and Leveraging Advocacy to Improve IDEA	Moderators: Dana Chase, MD Tara Castellano, MD
9:35 - 9:50 am	Institutional Barriers to Clinical Trials	John Farley, MD
9:50 - 10:05 am	Advocacy at the Local, Community and National Level to Improve IDEA	Speaker TBD
10:05 - 10:20 am	Q/A	
10:20 - 10:30 am	Coffee Break	
10:30 am	Session 3 – Clinical Trial Design and Implementation	Moderators: Amanda Jackson, MD Ana Tergas, MD
10:30 - 10:45 am	Eliminating Disparities: Careful Protocol Design	Roisin O’Cearbhaill, MD
10:45 - 11:00 am	Clinical Trial Implementation	Colleen McCormick, MD
11:00 - 11:20 am	Breakout 3: Black patient with Htn, DM and CrCl=40	
11:20 - 11:30 am	Q/A	
11:30 - 11:55 am	Session 3 – Diverse Patient Panel: Q and A (Panelists: Kimberly Richardson, Other panelists TBA)	Moderators: B. Pothuri, MD, MS J. Hines, MD
11:55 - 12:00 pm	Closing Remarks	

Registration Fee:

Symposium Registration fee is \$250. To Register visit: <https://www.nrgoncology.org/Meetings>

Protocol Support Committee

Introduction to Clinical Trials: Principles of NRG Oncology
Clinical Trial Management for Nurse/CRPs

Thursday, February 15, 2024

7:30 am - 4:30 pm ET

Offered as Virtual & In-Person



PROGRAM FACILITATORS

Cynthia Licavoli, RN, BSN, MA

Lauren Seames, MPH, CCRC

Marissa Weiss, MBA

MORNING PRESENTATIONS

Sharon Hartson Stine, MS, BA

NRG Oncology Overview

Karan Boparai, BS, (R)(M)

NRG Oncology Membership

Judy Langer, BS

Regulatory Affairs

Sara McCartney, MS, RN

Expedited Adverse Event Reporting

Brian Miller, PharmD

Investigational Drug Management

Joseph Mroziak

Medidata Rave

Mary Jo Antonelli, MBA, MHA

Quality Assurance Audits

Lisa Beaverson, BA, CCRP

Pathology/Biospecimen Collections

Shannon Puhalla, MD

RECIST Criteria

Nancy Fusco, RN, BSN, CCRP

Mentorship Program

Kandie Dempsey, DBA, MS, RN, OCN

PRO Compliance

AFTERNOON DISCUSSION SESSIONS

Patient Screening & Enrollment

Lead Facilitator: Cindy Licavoli, RN, BSN, MA

Erin McCaig, RN, BSN

Tiffany Elsea, BA, CCRP

Data Management

Lead Facilitator: Alex Kudryashev, MS, CCRP

Becky Kramer, RN, BSN, CCRC

Rachel Lacy, BA, MPH

Treatment Modalities in Clinical Trial Management

Lead Facilitator: Terry Thomas, MS, CCRC

Pamela Mason, RN, BSN, CCRP

Alison Ivey, RN, MS, MBA, OCN, CCRP

Adverse Event Reporting

Lead Facilitator: Cortney Montgomery BSN, RN, CCRP, CBCN

Stacey Lewis, RN, BSN, OCN

Brittany Lansford, CCRC

This activity has been approved with the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Session Title	Protocol Support Committee: Introduction to Clinical Trials: Principles of NRG Oncology Clinical Trial Management for Nurse/CRPs		
Date	February 15, 2024	Chair(s)	Terry Thomas, MS, CCRC
Time	7:30am - 4:30pm	Vice Chair(s)	Nancy Fusco, RN, BSN; Cynthia Licavoli, RN, BSN, MA
		Program Facilitators	Cynthia Licavoli, RN, BSN, MA; Lauren Seams, MPH, CCRC; Marissa Weiss, MBA
Room Location	Webinar / Canary		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss NRG Oncology membership requirements.
2. Identify and describe relevant regulations for federally funded clinical research involving human subjects.
3. Describe the processes to be followed by clinical research sites in adhering to IRB requirements.
4. Describe the key components of adverse event assessment for expedited reporting including seriousness criteria, term selection, grading and attribution.
5. Describe the standard drug accountability procedures for NCTN trials.
6. Identify and discuss resources regarding investigational drug management.
7. Discuss and navigate the Rave data management system.
8. Utilize basic commands to key data into the RAVE system.
9. Discuss the nature of and preparation for NCI-mandated Quality Assurance Audits.
10. Discuss the basics of pathology and translational research specimen requirements and submissions.
11. Describe the basic methodology of RECIST 1.1 and other response criteria used in NRG Oncology trials.
12. Discuss RECIST 1.1 criteria as well as other response criteria used and identify methods of source documentation.
13. Identify and discuss key components of Patient Reported Outcomes (PRO) compliance
14. Discuss NRG Oncology Mentorship Program.
15. Discuss patient screening and enrollment process and identify best practices.

16. Identify methods for screening patients for clinical trials.
17. Identify the informed consent process according to federal regulations and local practices.
18. Discuss protocol requirements for administration of chemotherapy, immunotherapy, radiation therapy and surgery.
19. Describe useful tools and methods to ensure timely and accurate data management in the clinical trial setting.
20. Identify proper forms of source documentation.
21. Describe procedures for completion and submission of case report forms.

Meeting Agenda

MORNING PRESENTATIONS

Time	Topic	Presenter
7:30-7:40am	Welcome	Cynthia Licavoli, RN, BSN, MA
7:40-7:50am	NRG Oncology Overview	Sharon Hartson Stine, MS, BA
7:50-8:10am	NRG Oncology Membership	Karan Boparai, BS, (R)(M)
8:10-8:35am	Regulatory Affairs	Judy Langer, BS
8:35-9:05am	Expedited Adverse Event Reporting	Sara McCartney, MS, RN
9:05-9:35am	Investigational Drug Management	Brian Miller, PharmD
9:35-9:50am	BREAK	
9:50-10:15am	Medidata Rave	Joseph Mroziak
10:15-10:45am	Quality Assurance Audits	Mary Jo Antonelli, MBA, MHA
10:45-11:05am	Pathology/Biospecimen Collections	Lisa Beaverson, BA, CCRP
11:05-11:40am	RECIST Criteria	Shannon Puhalla, MD
11:40-11:50am	Mentorship Program	Nancy Fusco, RN, BSN, CCRP
11:50am-12:00pm	Patient Reported Outcome Compliance	Kandie Dempsey DBA, MS, RN, OCN
12:00-12:05pm	Morning Closing Remarks	Cynthia Licavoli, RN, BSN, MA
12:05-1:30pm	Lunch break on your own	

AFTERNOON PRESENTATIONS

Time	Topic	Presenter
1:30-4:30pm	Patient Screening & Enrollment	Lead Facilitator: Cindy Licavoli, RN, BSN, MA Erin McCaig, RN, BSN Tiffany Elsea, BA, CCRP
	Treatment Modalities in Clinical Trials	Lead Facilitator: Terry Thomas, MS, CCRC Pamela Mason, RN, BSN, CCRP Alison Ivey, RN, MS, MBA, OCN, CCRP
	Data Management	Lead Facilitator: Alex Kudryashev, MS, CCRP Becky Kramer, RN, BSN, CCRC Rachel Lacy
	Adverse Event Reporting	Lead Facilitator: Cortney Montgomery, BSN, RN, CCRP, CBCN Stacey Lewis, RN, BSN, OCN Brittany Lansford, CCRC
4:25-4:30pm	Evaluation	

Protocol Support Committee

Nurse / Clinical Research Professional Continuing Educational Sessions

Friday, February 16, 2024

7:30- 11:45 am ET

Offered as Virtual & In-Person



PROGRAM FACILITATORS

Lauren Seames, MPH, CCRC
Marissa Weiss, MBA

AGENDA

Introduction & Welcome

Lauren Seames MPH, CCRC
Marissa Weiss, MBA

Research Operations Initiative Update

Jennifer Dill, BS, CCRP

Conquering Cancer Disparities through NRG Oncology Clinical Trials

Jennifer Wenzel, PhD, RN, CCM, FAAN

CTSU Updates

Krishna Chothwani, BA, ACRP-CP

PMB – AURORA Updates

Kayla Dye, PharmD

What We Don't Talk About When We Don't Talk About Sex & Cancer

Janelle Sobecki, MD

How to Manage Adverse Events

Stacey Lewis, RN, BSN, OCN, BBA
Audrie Walls, BSN, RN, OCN, CCRP
NRG Staff: Sara McCartney, MS, RN

Questions, Closing Remarks, Evaluations

Lauren Seames, MPH, CCRC &
Marissa Weiss, MBA

Session Title	Protocol Support Committee: Nurse/Clinical Research Professional Continuing Education Sessions		
Date	February 16, 2024	Chair(s)	Terry Thomas, MS, CCRC
Time	7:30 - 11:45am	Vice Chair(s)	Nancy Fusco, RN, BSN; Cynthia Licavoli, RN, BSN, MA
		Program Facilitators	Lauren Seams, MPH, CCRC; Marissa Weiss, MBA
Room Location	Webinar / Canary		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss current activities with the Research Operations Initiative as a result of the Site CRP Survey, identifying greatest challenges for sites with possible solutions.
2. Identify and discuss resources to address cancer disparities and engagement opportunities within the Health Disparities Committee.
3. Discuss, locate and describe current procedures and support services available with CTSU.
4. Discuss current PMB procedures and support services and explain how AURORA streamlines clinical trial conduct.
5. Discuss a systematic method of screening for sexual health concerns in oncologic practice.
6. Identify therapeutic resources for sexual health concerns in women with cancer.
7. Identify and discuss strategies for managing the collection and reporting of adverse events.

Meeting Agenda

Time	Topic	Presenter
7:30-7:40am	Introduction/Welcome	Lauren Seames, MPH, CCRC Marissa Weiss, MBA
7:40-8:05am	Research Operations Initiative Update	Jennifer Dill, BS, CCRP
8:05-8:35am	Conquering Cancer Disparities through NRG Oncology Clinical Trials	Jennifer Wenzel, PhD, RN, CCM, FAAN
8:35-9:10am	CTSU Updates	Krishna Chothwani, BA, ACRP-CP
9:10-9:35am	PMB – AURORA Updates	Kayla Dye, PharmD

9:35-9:50am	BREAK	
9:50-10:30am	What We Don't Talk About When We Don't Talk About Sex & Cancer	Janelle Sobecki, MD
10:30-11:35am	How to Manage Adverse Events	Stacey Lewis, RN, BSN, OCN, BBA Audrie Walls, BSN, RN, OCN, CCRP NRG Staff: Sara McCartney, MS, RN
11:35-11:45am	Questions, Closing Remarks, Evaluations	Lauren Seames, MPH, CCRC Marissa Weiss, MBA



Pathology Committee

Thursday, February 15, 2024

1:00-3:00pm ET

#NRG2024



Jeffrey Simko, MD, PhD
Committee Chair



Tanner Freeman, MD, PhD
Committee Co-Chair



Tan Ince, MD, PhD
Committee Co-Chair



Sandro Santagata, MD, PhD
Harvard University, Brigham & Women's Hospital
"Multiplexed Tissue Imaging in Pathology"



Tanner Freeman, MD, PhD
University of Pittsburgh Medical Center
"NRG Biobank Pittsburgh Update"



Jeffrey Simko, MD, PhD
University of California, San Francisco
"Translational Science Projects / Navigator (Digital Image Requests)"



Suzanne Baldwin
NRG Oncology
"Ancillary Projects (Digital Image Requests)"

Updates & Reports

Committee Updates
Committee Leadership

Disease Site Pathology Reports
Disease Site Pathologists

Session Title	NRG Pathology Committee		
Date	February 15, 2024	Chair(s)	Jeffry Simko, MD, PhD
Time	1:00 – 3:00pm	Vice Chair(s)	Tan Ince, MD, PhD; Tanner Freeman, MD, PhD
Room Location	Crystal A-C		

Learning Objectives

Following this activity, participants will be better able to:

1. Understand new technologies that can expand and extend the value of biospecimens for clinical use, patient management, and research applications.
2. Understand the utility, routes of access, and use of biospecimens in cooperative group research efforts.
3. Understand how pathologists can and are participating in the support of NRG clinical trial activities.

Meeting Agenda

Topic	Presenter
Multiplexed Tissue Imaging in Pathology – Challenges and Opportunities	Sandro Santagata, MD, PhD <i>Brigham & Women's Hospital, Harvard College</i>
NRG Biobank Pittsburgh Update	Tanner Freeman, MD, PhD <i>University of Pittsburgh Medical Center</i>
Committee Updates	Jeffry Simko, MD, PhD <i>University of California, San Francisco</i> Tan Ince, MD, PhD <i>Weill Cornell Medicine</i>
Translational Science Projects / Navigator (Digital Image Requests)	Jeffry Simko, MD, PhD
Ancillary Projects (Digital Image Requests)	Suzanne Baldwin <i>NRG Oncology</i>
Disease Site Pathology Reports	Disease Site Pathologists
QUESTIONS / DISCUSSION	



Early Career & New Investigator (ECNI) *Educational Session*

Thursday, February 15, 2024

2:30-4:00pm

#NRG2024

#NRG10



Deborah Watkins Bruner, RN, PhD

NRG NCORP Contact PI

Winship Cancer Institute of Emory University

"NCORP Opportunities for Career Development"



Tara Berman, MD

Dana-Farber Cancer Institute

**"FDA Approved?... Understanding the
Regulatory Process"**



Paul Nguyen, MD

Dana-Farber Cancer Institute

Brigham and Women's Hospital

**"Trajectory for a Successful Early
Career Investigator"**



Vassilios Pinopoulos

NRG Oncology

"ECNI Learning Modules"



Shlomo Koyfman, MD

Cleveland Clinic



Marlyn Molero

NRG Patient Advocate

"Enrolling Patients on Clinical Trials"

**To be
immediately
followed by
the Early
Career & New
Investigator
(ECNI)
Networking
Session from
4:00-5:00pm.**

Session Information

Session Title	ECNI Educational Session		
Date	February 16, 2024	Chair(s)	Vinai Gondi, MD
Time	2:30 – 4:00pm ET	Vice Chair(s)	Priya Rastogi, MD, Angeles Secord, MD
Room Location	Magnolia 13-15		

Meeting Agenda

Time	Topic	Presenter
2:30 – 2:35pm	Opening Remarks	Vinai Gondi, MD
2:35 – 2:50pm	NCORP Opportunities for Career Development	Deborah Watkins-Bruner, RN, PhD
2:50 – 3:05pm	FDA Approved?... Understanding the Regulatory Process	Tara Berman, MD
3:05 – 3:20pm	Trajectory for a Successful Early Career Investigator	Paul Nguyen, MD
3:20 – 3:25pm	ECNI Learning Modules	Vassilios Pinopoulos
3:25 – 3:45pm	Enrolling Patients on Clinical Trials	Shlomo Koyfman, MD Marlyn Molero, NRG Patient Advocate
3:45 – 3:55pm	Panel for Questions & Answers	
3:55 – 4:00pm	Closing Remarks	Vinai Gondi, MD

Additional Notes:

The Early Career & New Investigator Networking Session will be held immediately following from 4:00-5:00pm ET in Magnolia 16-18.



Translational Science Committee

Thursday, February 15, 2024

3:00-5:00pm ET

The Role of Spatial Biology in Oncology: Opportunities & Challenges for Translational Research



Michael Birrer, MD, PhD
Committee Chair



Adam Dicker, MD, PhD
Committee Co-Chair



Vered Stearns, MD
Committee Co-Chair



Nicholas Reder, MD, MPH
Alpenglow Biosciences
"3D Spatial Biology of Archived FFPE Tissue"

Espy Anguiano, PhD, MS-MBA
Nanostring Technologies

**"Breaking Barriers in Cancer Treatment:
New Insights and Opportunities from Spatial Biology"**



Sandro Santagata, MD, PhD
Harvard University
**"Multiplexed Tissue Imaging for Biomarker and Translational
Science Discovery"**

Hartland Jackson, PhD
University of Toronto

**"Whole Slide Imaging Mass Cytometry Enables Rapid Profiling
of Tumor Spatial Heterogeneity and Immune
Microenvironments"**



Session Title	NRG Translational Science Committee “The Role of Spatial Biology in Oncology: Opportunities & Challenges for Translational Research”		
Date	February 15, 2024	Chair(s)	Michael Birrer, MD, PhD
Time	3:00 – 5:00pm	Vice Chair(s)	Adam Dicker, MD, PhD, Vered Stearns, MD
Room Location	Canary		

Learning Objectives

Following this activity, participants will be better able to:

1. Recognize spatial biology as a tool to understand interactions within the tumor microenvironment
2. Recognize spatial biology as an important biomarker
3. Understand the technology behind spatial genomics
4. Understand translational science in NRG Oncology
5. Understand the role of the biorepositories in translational science

Meeting Agenda

Topic	Presenter
3D Spatial Biology of Archived FFPE Tissue	Nicholas Reder, MD, MPH <i>Alpenglow Biosciences, Inc.</i>
Breaking Barriers in Cancer Treatment: New Insights and Opportunities from Spatial Biology	Espy Anguiano, PhD, MS-MBA <i>Nanostring Technologies</i>
Multiplexed Tissue Imaging for Biomarker and Translational Science Discovery	Sandro Santagata, MD, PhD <i>Harvard University</i>
Whole Slide Imaging Mass Cytometry Enables Rapid Profiling of Tumor Spatial Heterogeneity and Immune Microenvironments	Hartland Jackson, PhD <i>University of Toronto</i>
QUESTIONS / DISCUSSION	



General Session

Friday, February 16, 2024

12:00-1:00 pm ET

#NRG2024



Quynh-Thu Le, MD
NRG Group Chair



Robert Mannel, MD
NRG Group Chair



Norman Wolmark, MD
NRG Group Chair



Mitchell Machtay, MD
*NRG Research Center
Update*



David Miller, MD
*NRG Membership
Update*



James Dignam, PhD
NRG SDMC Update



**Deborah Watkins
Bruner, RN, PhD**
*NRG NCORP Research
Base Update*



**Jeffry Simko, MD,
PhD**
*NRG Biospecimen
Bank Update*



Harry Bear, MD
*NRG Publications &
Communications
Update*

Session Information

Session Title	General Session		
Date	February 16, 2024	Chair(s)	Quynh-Thu Le, MD, Robert Mannel, MD, Norman Wolmark, MD
Time	12:00 – 1:00pm ET	Vice Chair(s)	
Room Location			

Meeting Agenda

Time	Topic	Presenter
12:00 – 12:15pm	Welcome, Group Updates, and Highlights	Robert Mannel, MD, NRG Oncology Group Chair
12:15 – 12:20pm	NRG Research Center Update	Mitchell Machtay, MD, NRG Oncology Deputy Group Chair
12:20 – 12:25pm	NRG Membership Update	David Miller, MD, NRG Oncology Deputy Group Chair
12:25 – 12:30pm	NRG SDMC Update	James Dignam, PhD, NRG Oncology Group Statistician
12:30 – 12:35pm	NRG NCORP Research Base Update	Deborah Watkins Bruner, RN, PhD, NCORP PI
12:35 – 12:40pm	NRG Biospecimen Bank Update	Jeffry Simko, MD, PhD, NRG Oncology Biospecimen Bank PI
12:45 – 12:50pm	NRG Publications & Communications Update	Harry Bear, MD, PhD, NRG Oncology Deputy Group Chair
12:50 – 1:00pm	Questions & Closing Remarks	Robert Mannel, MD, NRG Oncology Group Chair

Additional Notes:



Scientific Session

Friday, February 16, 2024

3:00-4:30 pm ET

#NRG2024



James C. Yao, MD
*Accelerating clinical
trial builds in electronic
health records (HER)*



Mitchell Machtay, MD
*NRG-RTOG 0920
Presented at the American
Society for Radiation
Oncology 2023 Annual
Meeting.*



Vinai Gondi, MD
*NRG-CC003
American Society for
Radiation Oncology
2023 Annual Meeting.*



**Eleftherios
Mamounas, MD**
*NRG-NSABP B-
51/RTOG 1304
Presented at the 2023
San Antonio Breast
Cancer Symposium.*



Aine Clements, MD
*NRG-GOG 0283
Presented at the
International
Gynecologic Cancer
Society 2023 Annual
Meeting.*



Ramez Eskander, MD
*NRG-GY018
Presented at the
European Society for
Medical Oncology
2023 Annual Meeting.*



Andrew Lassman, MD
*NRG-BN007
Presented at the
European Association
of Neuro-Oncology
2023 Annual Meeting.*

Session Title	Scientific Session		
Date	February 16, 2024	Chair(s)	Quynh-Thu Le, MD, Robert Mannel, MD, Norman Wolmark, MD
Time	3:00 - 4:30pm ET	Vice Chair(s)	
Room Location	Sabal		

Learning Objectives

Following this activity, participants will be better able to:

1. Review and discuss the issues related to building clinical trial requirements in electronic health record systems.
2. Explain the impact on overall survival and disease free survival for patients treated with radiotherapy and cetuximab who have intermediate-risk squamous cell carcinoma of the head and neck
3. Discuss the results of a phase IIR/III study of prophylactic cranial irradiation with or without hippocampal avoidance for patients with small cell lung cancer.
4. Discuss the role of adjuvant regional nodal irradiation for patients whose breast cancer converted from lymph node–positive to lymph node–negative disease after neoadjuvant chemotherapy
5. Discuss if molecular classification using mismatch repair (MMR) and p53 protein expression predicts relapse-free survival in endometrial cancer patients treated with chemotherapy and radiation versus chemotherapy alone.
6. Discuss the observation that no difference in progression-free survival was seen in dMMR endometrial cancer patients based on the mechanism of MMR loss
7. Discuss the results of a phase II/III trial for patients with unmethylated newly diagnosed glioblastoma treated with of ipilimumab plus nivolumab vs. temozolomide

Meeting Agenda

Time	Topic	Presenter
3:00 – 3:05pm	Welcome and Opening Remarks	Robert Mannel, MD, NRG Oncology Group Chair

3:05 – 3:25pm	Accelerating clinical trial builds in electronic health records (HER)	James C. Yao, MD, MD Anderson Cancer Center
3:25 – 3:35pm	NRG-RTOG 0920: Randomized Phase III trial of postoperative radiotherapy with or without cetuximab for intermediate-risk squamous cell carcinoma of the head and neck (SCCHN). <i>Presented at the American Society for Radiation Oncology 2023 Annual Meeting.</i>	Mitchell Machtay, MD, NRG Oncology Deputy Group Chair, NRG-RTOG 0920 Principal Investigator
3:35 – 3:45pm	NRG CC003: Phase IIR/III trial of prophylactic cranial irradiation (PCI) with or without hippocampal avoidance (HA) for small cell lung cancer (SCLC). <i>American Society for Radiation Oncology 2023 Annual Meeting.</i>	Vinai Gondi, MD, NRG Oncology ECNI Committee Chair, NRG-CC003 Principal Investigator
3:45 – 3:55pm	NRG-NSABP B-51/RTOG 1304: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304. <i>Presented at the 2023 San Antonio Breast Cancer Symposium.</i>	Eleftherios Mamounas, MD, NRG Oncology Breast Cancer Committee Chair, NRG-NSABP B-51/RTOG 1304 Principal Investigator
3:55 – 4:05pm	NRG-GOG 0283: Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) outcomes: Ancillary analysis of GOG-0258. <i>Presented at the International Gynecologic Cancer Society 2023 Annual Meeting.</i>	Aine Clements, MD, Ohio State University Comprehensive Cancer Center, Ancillary Project Principal Investigator
4:05 – 4:15pm	NRG GY018: Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial. <i>Presented at the European Society for Medical Oncology 2023 Annual Meeting.</i>	Ramez Eskander, MD, UC San Diego Moores Cancer Center, NRG-GY018 Principal Investigator
4:15 – 4:25pm	NRG BN007: Randomized phase II/III trial of ipilimumab (Ipi) plus nivolumab (Nivo) vs. temozolomide (TMZ) in MGMT-unmethylated (uMGMT) newly diagnosed glioblastoma (nGBM). <i>Presented at the European Association of Neuro-Oncology 2023 Annual Meeting.</i>	Andrew Lassman, MD, Columbia University Irving Medical Center, NRG- BN007 Principal Investigator
4:25 – 4:30pm	Closing Remarks	Robert Mannel, MD, NRG Oncology Group Chair

Additional Notes:



NRG NCORP *Town Hall*

Friday, February 16, 2024

10:00-11:30am

#NRG2024

#NRG10



Deborah Bruner, PhD, RN

NRG NCORP Contact PI

Winship Cancer Institute of Emory University

"Welcome"

"NRG NCORP Updates"



Tribute to Dr. Wortia MCaskill-Stevens

by Dr. Deborah Watkins Bruner and Dr. Joan Walker



Brandy Heckman-Stoddard, MD

Acting Director, NCI Community Oncology Research Program

"NCI NCORP Priorities"

NCI Updates

Sandra Russo, MD

Community Oncology and Prevention Trials Research Group, DCP

"NCI NCORP Update"

Kathleen Castro, RN, MS

Nurse Consultant

Office of the Associate Director of the Healthcare Delivery Research Program

"NCI CDDR Update"

Session Title	NRG NCORP Town Hall		
Date	February 16, 2024	Chair(s)	Deborah Bruner, PhD, RN ; Joan Walker, MD
Time	10:00 - 11:30am	Vice Chair(s)	Lisa Kachnic, MD
Room Location	Crystal G1		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss proposed and ongoing NRG NCORP research trials.
2. Apply procedures required to implement a protocol within NCORP
3. Learn about opportunities in CCDR and CPC clinical trials.

Meeting Agenda

Time	Topic	Presenter
10:00-10:20am	Welcome, NRG NCORP Updates	Deborah Bruner, PhD, RN, FAAN, NRG NCORP PI
10:20-10:30am	Tribute to Dr. McCaskill-Stevens	Deborah Bruner, PhD Joan Walker, MD
10:30-10:45am	NCI NCORP Priorities	Brandy Heckman-Stoddard, MD Acting Director NCI Community Oncology Research Program
10:45-10:55am	Questions / Discussion	
10:55-11:05am	NCI NCORP Update	Sandra Russo, MD Community Oncology and Prevention Trials Research Group, DCP
11:05-11:15am	NCI CCDR Update	Kathleen Castro, RN, MS Nurse Consultant Office of the Associate Director of the Healthcare Delivery Research Program
11:15-11:30am	Questions / Discussion	

NRG-CC005 FORTE Workshop

February 16, 2024

1:15-2:30 PM ET



Robert Schoen, MD, MPH

*Principal Investigator/
Study Chair
University of Pittsburgh
@rockscho*



Jeffrey Dueker, MD, MPH

*Protocol Co-chair
University of Pittsburgh
@DuekerJeffrey*



Cheryl Leow, MA

*FORTE Education and
Communication Specialist
NRG Oncology
@FORTEStudy*

NCORP Chairs

**Deborah Watkins
Bruner, RN, PhD, FAAN**
*NCORP Contact Principal
Investigator*

Lisa Kachnic, MD
Associate NCORP Chair

 FORTE Study

 @FORTEStudy

 FORTE Study

 @FORTEStudy



Carolyn Beebe, RN, CTRN II

*Kaiser Permanente Northern
California*

Jasmine Deras, MSBH

*Kaiser Permanente Northern
California*

#NRG2024

#FORTEStudy

Session Information

Session Title	FORTE Workshop		
Date	February 16, 2024	Chair(s)	Robert Schoen, MD, MPH
Time	1:15-2:30pm	Vice Chair(s)	Jeffrey Dueker, MD, MPH
Room Location	Crystal G1		

Meeting Agenda

Time	Topic	Presenter
1:15pm	Welcome	Deborah W. Bruner, RN, PhD, FAAN, NCORP Contact PI
1:20pm	Overview of FORTE Trial Progress	Robert Schoen, MD, MPH FORTE Protocol Chair
1:25pm	Protocol Practices for FORTE Success	Robert Schoen, MD, MPH FORTE Protocol Chair
1:35pm	How to Discuss FORTE with Gastroenterologists	Jeffrey Dueker, MD, MPH FORTE Protocol Co-Chair
1:50pm	FORTE Enrollment at Kaiser Permanente North California	Carolyn Beebe, RN, CTRN II Jasmine Deras, MSBH Kaiser Permanente Northern California
2:05pm	Promoting FORTE within your Clinical Research Network	Cheryl Leow, MA FORTE Education and Communications Specialist
2:10pm	QUESTION AND ANSWER	
2:25pm	Call to Action	Robert Schoen, MD, MPH FORTE Protocol Chair



Social Media Workshop

Monday, February, 2024

4:00-5:00 pm EST

Virtual Session

#NRG2024 #NRG10



Kristin A. Higgins, MD

Workshop Chair

Winship Cancer Institute of Emory University

ⓧ @KHigginsMD

📷 @khigkies

**Recording available following
the NRG Meeting.**



Miriam Knoll, MD, DABR

Workshop Chair

Northshore LIJ

ⓧ @MKnoll_MD

📷 @dr.mimi.k

Leveraging Social Media for Lung Cancer

Advocacy & Survivorship

Kristen Kimball, MS, MEM

Retired Physiology Instructor

Lung Cancer Advocate

Boston, MA

ⓧ @KimballKristen

#BTS on The Targeting Cancer Campaign

**Lucinda Morris, BA, MBBS, FRANZCR, Grad Cert
(Clinical Redesign)**

Radiation Oncologist

Co-Chair, Targeting Cancer

Sydney, Australia

ⓧ @lucindamorris23



Session Title	Social Media Workshop		
Date	February 12, 2024	Chairs	Miriam Knoll, MD & Kristin Higgins, MD
Time	4:00-5:00 pm EST		
Room Location	Virtual via Zoom		

Session Information

Learning Objectives

Following this activity, participants will be better able to:

1. To understand the paradigm shifts in oncology using social media
2. To understand the importance of patient advocacy using social media
3. To gain knowledge how social media helps with clinical trial recruitment

Meeting Agenda

Time	Topic	Presenter
4:00-4:05pm	Welcome & Introductions	Drs. Knoll & Higgins
4:05-4:25pm	Leveraging Social Media for Lung Cancer Advocacy and Survivorship	Kristen Kimball, MS, MEM <i>Boston, MA</i> • Retired Physiology Instructor • Lung Cancer Advocate
4:25-4:45pm	#BTS on The Targeting Cancer Campaign Initiative of the Faculty of Radiation Oncology of the Royal Australian and New Zealand College of Radiologists	Lucinda Morris, BA, MBBS, FRANZCR, Grad Cert (Clinical Redesign) <i>Sydney, Australia</i> • Radiation Oncologist • Co-chair, Targeting Cancer
4:45-5:00pm	Questions / Discussion	All

Additional Notes:

Social media is increasingly used by physicians and patients. Over the past few years, many paradigm shifts in medicine have been facilitated via social media discussions. Physicians will benefit from learning how to use these tools to advance medicine. This panel will discuss how social media helps with clinical trial recruitment from both the physician and patient perspective.

10 Years
NRG
ONCOLOGY
2024 WINTER MEETING

NRG Oncology

CME/Non-CME Agendas

Session Information

Session Title	Brain Committee General Meeting		
Date	February 16, 2024	Chair(s)	Minesh Mehta, MD
Time	1:15-2:45pm	Vice Chair(s)	Mark Gilbert, MD; Michael Vogelbaum, MD; Arnab Chakravarti, MD; Mei Polley, PhD
Room Location	Crystal H		

Meeting Agenda

Time	Topic	Presenter
1:15-1:30pm	NRG GBM PORTFOLIO	
	NRG-BN010	Bagley
	NRG-BN011	Iwamoto
	A701702	Jing Wu
1:30-2:05pm	NRG BRAIN METASTASES PORTFOLIO	
	NCCTG CE 7	Roberge
	NRG-BN009	Gondi/Chan
	NRG-BN012	Burri
	NRG-CC009	Gondi
	S2000	Kotecha
	NRG-BN013	Kotecha
	NRG-BN014	Yang
2:05-2:15pm	NRG LOWER GRADE GLIOMA PORTFOLIO	
	NRG-BN005	Grosshans
	1071 (Alliance CODEL)	Vogelbaum
2:15-2:25pm	NRG OTHER TUMORS PORTFOLIO	
	NRG-BN003	Rogers
	ACNS 2021: NGGCT	Hall

Session Title	Breast Cancer Workshop		
Date	February 17, 2024	Chair(s)	Eleftherios Mamounas, MD
Time	9:45-11:45am	Vice Chair(s)	Julia White, MD; Charles Geyer, MD; Mothaffar Rimawi, MD
Room Location	Royal		

Learning Objectives

Following this activity, participants will be better able to:

1. Identify and describe the design and status of new and ongoing breast cancer clinical trials.
2. Identify and describe new forms of radiotherapy delivery and their use in breast cancer trials.
3. Identify and describe systemic therapies, including chemotherapeutic drugs, hormonal strategies, biologic agents, new classes of targeted therapies, and immunotherapy that may be used in breast cancer treatment clinical trials.

Meeting Agenda

Time	Topic	Presenter
9:45-10:15am	Report from the Breast Working Group Meeting NSABP B-51/RTOG 1304: SABCS Presentation	Eleftherios Mamounas, MD Julia White, MD
10:15-10:30am	BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Breast Cancer with a Low Oncotype Recurrence Score	Julia White, MD
10:30-10:45am	BR008: A Phase III Randomized Trial Evaluating Omission of Breast Radiotherapy for Low-Risk HER2-Positive Breast Cancer	Lior Braunstein, MD Melissa Mitchell, MD, PhD
10:45-11am	BR009: Chemotherapy plus ET vs. Ovarian Ablation plus ET in Early-Stage Hormone-Positive Premenopausal Women with Oncotype < 25 (OFSET CHEMO)	Shannon Puhalla, MD Eleftherios Mamounas, MD Sandra Swain, MD
11:00-11:15am	COMPASS HER2-RD: Postneoadjuvant T-DM-1 + Tucatinib or Placebo in HER2-Positive Patients with Residual Disease Following Preoperative Therapy	Virginia Borges, MD
11:15-11:30am	SWOG S2206: Phase III Trial of Neoadjuvant Durvalumab plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor Positive / HER2-Negative Stage II-III Breast Cancer	Julia Foldi, MD, PhD
11:30-11:45am	EAY191-N2 (ComboMATCH): Phase 2 Trial of Fulvestrant and Binimetinib in Patients with HR-Positive Metastatic Breast Cancer with a Frame Shift or Nonsense Mutation or Genomic Deletion in NF1	Bora Lim, MD

Session Title	Canadian Subcommittee Meeting		
Date	February 15, 2024	Chair(s)	Jean-Paul Bahary, MD
Time	10:00-11:00am	Vice Chair(s)	Al Covens, MD
Room Location	Virtual / Magnolia 4 – 6		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the status and significance of new and ongoing NRG Oncology clinical trials available in Canada
2. Discuss and subsequently apply standards and procedures required to participate in a research protocol supported by NRG Oncology
3. Learn about trials available in Canada

Meeting Agenda

Time	Topic	Presenter
10:00-10:05am	Welcome, Introductions Canadian representative appointed to NRG Patient Advocacy Committee – Welcome	Jean-Paul Bahary, MD
10:05-10:25am	NRG-GU013: The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer	Scott Morgan, MD
10:25-10:30am	Audit trends and remote auditing	Mary Jo Antonelli
10:30-10:35am	Status of NRG Oncology Trials in Canada Accrual update (January 1, 2023 – December 31, 2023)	Erica Field
10:35-10:45am	Development of CCTG and NRG ICF templates	Jean-Paul Bahary, MD
10:45-11:00am	Questions / Discussion	

Session Title	Cancer Care Delivery Research Committee		
Date	February 15, 2024	Chair(s)	Mary E. Cooley, PhD
Time	11:30am-1:00pm	Vice Chair(s)	Matthew F. Hudson, PhD
Room Location	Virtual / Royal		

Learning Objectives

Following this activity, participants will be better able to:

1. Discussed proposed and ongoing NRG cancer care delivery research trials.
2. Discuss proposed and ongoing NRG cancer care delivery research trials and cross-cutting aims with disparities.
3. Identify and prioritize areas of unmet need in cancer care delivery research.
4. Apply procedures required to design, submit, and implement a research protocol for support by the NRG.

Meeting Agenda

Time	Topic	Presenter
11:30-11:40am	Welcome, Introductions	Mary E. Cooley, PhD
11:40am-12:00pm	Developing protocol: NRG-CC012CD, Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment	Tracy Crane, PhD
12:00-12:20pm	Pilot project results: Leveraging mHealth to improve symptom management and adherence of oral chemotherapy for women with non-metastatic triple negative breast cancer	Ilana Graetz, MD
12:20-12:50pm	Patient engagement in research	Grace Campbell, MD Heidi Donovan, PhD Tambre Leighn Laurel Pracht
12:50-1:00pm	Questions/Discussion	

Session Title	Cancer Care Prevention and Control Committee		
Date	February 15, 2024	Chairs	Lisa Kachnic, MD; Warner Huh, MD
Time	1:00pm – 2:30pm	Vice Chairs	Julie Bauman, MD; Tracy Crane, PhD
Room Location	Royal		

Session Information

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss ongoing and proposed NRG clinical trials on cancer prevention and control.
2. Discuss recruitment and enrollment strategies on ongoing trials.
3. Discuss multi-disciplinary aspects of ongoing and proposed clinical trials in each of the primary disease sites.
4. Identify and prioritize areas of unmet need in cancer prevention and control research in each of the primary disease sites.
5. Identify and discuss the results and publication status of NRG CPC clinical trials recently completed.
6. Apply procedures required to design, submit and conduct a research protocol for support by NRG.

Meeting Agenda

Time	Topic	Presenter
1:00 – 1:10pm	Welcome, Introductions	Lisa Kachnic, MD, FASTRO
1:10 – 1:25pm	Overview of Open NRG CPC trials NRG-CC005 NRG-CC008 NRG-CC009 NRG-CC010	Robert Schoen, MD Warner Huh, MD Vinai Gondi, MD Britt Erickson, MD
1:25 – 1:35pm	NRG-CC011, Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial.	Diane Von Ah, PhD
1:35 – 1:45pm	NRG-CC2223: Mindfulness Meditation for Younger Breast Cancer Survivors: Testing Digital Interventions in Clinical and Community Settings	Patti Ganz, MD

1:45 – 1:55 pm	Developing protocol: NRG-CC013, A Randomized, Masked, Placebo Controlled, Phase II Trial of Concurrent Chemoradiation with BMX-001 in Patients with Head and Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation	Christina Chapman, MD
1:55 – 2:05pm	Developing concept: NRG-CC2327, Radiation Therapy for High-risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial	Jonathan Yang, MD
2:05– 2:15pm	Developing concept: Phase II Randomized Trial of Nanogenistein in Combination with Chemoradiotherapy and Immunotherapy for Locally Advanced and Oligometastatic NSCLC	Charles Simone, MD
2:15 – 2:30pm	Q&A/Discussion	

Session Title	Cervix Workshop		
Date	February 16, 2024	Chair(s)	Charles A. (Trey) Leath, III, MD, MSPH
Time	8:00-10:00am	Vice Chair(s)	Jyoti Mayadev, MD; Dmitriy Zamarin, MD, PhD
Room Location	Sago		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss national and international priorities, goals and initiatives in the management of cervical cancer
2. Discuss currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of cervical and vulvar cancers
3. Discuss promising therapeutics in development and potential translational research objectives and strategies for future clinical trials
4. Apply standards and procedures needed to design, submit, (revise), and conduct a research protocol within the NRG
5. Outline both potential barriers and potential solutions to improve enrollment to NRG clinical trials in cervical and vulvar cancer to include international collaboration
6. **Educational Needs:** To increase the medical awareness of cervical cancer unmet needs and clinical trial development.

Meeting Agenda

Topic

Introduction / Announcements

- Welcome, committee membership and rotation plan and review of July 2023 minutes
 - Annual rotation of approximately 10% from CORE committee
- Cervix updates from the task forces/Patient Advocate
 - Cervical Cancer Task Force (Boyd)
 - Cervical Cancer Task Force (Junior Investigator) (Jegadeesh)
 - Cervical Cancer Patient Advocate (Williams)

Educational Session

- KEYNOTE A18: ESMO results and implications (Duska)
- Committee remarks

New Concepts

Previously committee-approved/reviewed concepts. Current updates and future directions.

- **CV2346:** Chemoradiation with or without Checkpoint Inhibition in Lymph Node Positive Carcinoma of the Vulva. (Scott Glaser) Previously CV1964
- **CV2332:** A Phase I/II randomized non inferiority trial of hypofractionated IMRT with concurrent cisplatin and brachytherapy for cervical cancer versus conventional standard of care. (Henson/Moore/Mayadev)

- **CV2305: STRIVE Study:** STRatification of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision. (McAlpine/Jamieson : CCTG Salani/Gien : NRG)

Concepts in Development; Brief Updates

- **CV2401:** Immune Priming with Neoadjuvant Immunotherapy and Chemotherapy vs. Chemoradiation followed by immunotherapy for Locally Advanced Cervical Cancer, N=480 (Mayadev, Zamarin)

Operational Management On-going NRG Trials

Closed Studies

- Protocols: 101, 120, 205, 222, 141, 173, 179, 204, 206, 240, 233, 9806

Active / Recently Completed Trials

- **NRG-GY024:** Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Slomovitz) N=157
- **GOG-0724/RTOG0724:** Phase III trial randomized study of concurrent chemotherapy and pelvic RT with or without adjuvant chemotherapy in high-risk patients with early stage cervical carcinoma following radical hysterectomy. (Heidi Gray, Anuja Jhingran)
 - Opened April 2009
 - Closed
 - Accrual 236/285 (82.8%)
 - Final analysis: to report out early 2024; goal of ASCO presentation deadline 2024
- **GOG-0263:** Randomized clinical trial for adjuvant chemoradiation in post-operative cervical cancer patients with intermediate risk factors (Sang Young Ryu, Kevin A)
 - Opened April 2010
 - Amended Nov 2017 to decrease accrual from 534 to 360
 - Closed
 - Accrual 339/360 (94.2%)
 - Final analysis March 2024 (2 yrs post final accrual as the events are very slow)
- **GOG-0278:** Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy for stage IA1-IB1 (≤ 2 cm) cervical cancer. (Al Covens)
 - Opened October 1, 2012
 - PET imaging amendment approved July 2015
 - Accrual 220/220 (100%)
 - Final analysis of the 6 month PRO and survivals to be performed fall of 2023; goal of SGO 2023 or ASCO 2023; will try to coordinate w Shape results if possible
- **GOG-0279:** A phase II trial evaluating cisplatin and gemcitabine concurrently with intensity-modulated radiation therapy (IMRT) for the treatment of locally advanced squamous cell carcinoma of the vulva. (Neil S. Horowitz)
 - Opened July 2, 2012
 - Temporarily Closed June 15, 2015 after enrolling 28 in 1st stage
 - 2nd stage re-opened July 2016
 - Accrual completed
 - Final analysis report completed May 2022
 - At journal review for primary MS
- **NRG-GY006:** A randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA Cancer of the uterine cervix or Stage II-IVA vaginal cancer. (Trey Leath, Loren Mell)
 - Opened January 15, 2016
 - Amendment to CTEP re: increase in accrual size and transition to Randomized phase 3
 - Temporarily closed secondary to drug shortage May 28, 2021
 - Accrual complete
- **NRG-GY017:** Phase I trial using anti PD-L1 (atezolizumab) as immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer. (Jyoti Mayadev)
 - Opened October 26, 2018
 - Accrual: 40/40

- Presentation SGO 2022 and SGO 2023; final analysis report to be performed Oct 2022, at journal for primary MS

Reports from Other Committees and Groups

- Publications Subcommittee
- Patient Center Outcomes Research Committee
- Ancillary Data Committee
- Cancer Prevention and Control
- Rare Tumor Committee
- Vaccine Subcommittee
- Pathology Committee
- Radiation Committee
- SPORE Committee
- Nursing
- Medical Oncology
- Patient/Community/Advocacy

Concluding Remarks and Wrap-up

QUESTIONS / DISCUSSION

Session Title	Developmental Therapeutics Committee		
Date	February 15, 2024	Chair(s)	Roisin O’Cearbhaill, MD Translational Research Chair : Panagiotis Konstantinopoulos, MD, PhD
Time	12:30-2:30pm	Vice Chair(s)	Floor Backes, MD (Phase II) Russell Schilder, MD (Phase I) Stephanie Gaillard, MD, PhD (Phase I)
Room Location	Sago		

Learning Objectives

Following this activity, participants will be better able to:

1. Participants will become familiar with the current status of translational research projects involving phase I and II studies that are under development or activated for accrual.
2. Participants will become familiar with the early identification and management of immunotherapy-related toxicities.
3. Clinical data related to novel investigational agents will be reviewed.
4. Recommendations for action by the GYN Developmental Therapeutics committee will be summarized.

Meeting Agenda

Topic

Introduction, Dr. O’Cearbhaill and Dr Backes. Welcome.

Review of opportunities for new investigators and discuss committee rotation.

Welcome new members.

Congratulate Dr Russell Schilder.

Presentation of open active studies

GY022, GY025, GY027, GY028, GY031, GY034, EAY191-N4

Review new concepts

DT2413: A Single-Arm, Phase II Evaluation of Durvalumab and Tremelimumab for Recurrent or Metastatic Ovarian and Uterine Clear Cell Carcinoma with PPP2R1A Loss-of-function Mutations (PI: Lin), Reviewers Fuh/Landen/Adams

DT2408: Phase II Study of Immunotherapy plus Oral Selinexor as Maintenance Therapy in p53 Wildtype Advanced/Recurrent Endometrial Cancer (PI: Silk/Pothuri/Makker) Reviewers Zamarin/Oladapo/Westin

Review concepts from disease subcommittees. UC2409, UC2410, OV2412, OV2414

UC2409 A Phase II trial of Giredestrant with Abemaciclib in Patients with Advanced or Recurrent ER+ Leiomyosarcoma with CDKN2A deletion and intact RB1 (Bose, Hensley)

UC2410 A Phase II Randomized Trial of Adjuvant Gemcitabine/Docetaxel versus Adriamycin/Trabectedin Chemotherapy in Uterine Leiomyosarcoma. (Haddad, Soliman).

OV2412 Phase II Study of Adjuvant Trastuzumab Deruxtecan for HER2 Expressing High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSOC) after Suboptimal Response to Neoadjuvant Platinum-based Chemotherapy. (Yadav, Hendrickson).

OV2414 GnRH (Elagolix) Antagonism in platinum-resistant ovarian cancer: a single-arm phase II trial (GREAT trial) (Mallen, Conejo-Garcia)

Early identification of immunotherapy-related toxicity Drs. Kathleen Moore, Haider Mahdi, Roisin O’Cearbhaill, Stephanie Gaillard

Update on studies under development

DT/RT2321 Exportin 1 inhibitor, eltanexor, in patients with recurrent low-grade serous ovarian carcinoma; a phase II non randomized study. (Nasioudis/Simpkins)

EAY191-N5 Phase II study of TKI and CDK4/6i in HER2+ (Mahdi)

Phase 1 committee updates (Gaillard/Schilder)

ComboMATCH and iMATCH update (O’Cearbhaill)

- EAY191-N5 (Mahdi)
- N6 needs phase I (Liu)
- S2101

Open discussion, closing remarks. LOI to Kia: deadline June for July meeting

GYNconcepts@nrgoncology.org

List of Studies

Active PK Studies:

- **NRG-GY022:** Assessment of carboplatin clearance predictors: a companion PK study to NCI sponsored clinical trials or standard of care treatments using carboplatin (Sarah Taylor/Jan Beumer)
 - 261/350 enrolled
 - Open up to male participants only now

Active Phase I Studies:

- **GY027:** Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Carboplatin and Paclitaxel with Ipatasertib in Epithelial Ovarian Cancer (Fuh/Moore)
 - Open to accrual 6/27/22: 12/24 enrolled
 - Reminder about weekly Friday 3:30 PM safety calls.
- **GY028 (PTMA #100828):** Phase IB and randomized phase II trial of medroxyprogesterone acetate +/- ipatasertib in recurrent/metastatic endometrioid endometrial cancer (Onstad Grinsfelder/Westin)
 - Opened 1/13/23 ; 6/18 enrolled. Reopened to accrual phase 2
- **NRG-GY031:** A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer (Andriani/Simpkins).
 - Opened 8/31/23 ; 2/42-57 enrolled
- **NRG-GY034:** A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel with or without Bevacizumab in Patients with Recurrent Epithelial Ovarian Cancer (Zeligs/Annunziata/Moore) n76

Safety Lead-in:

- **NRG-GY025:** A randomized phase II trial of immunotherapy with dual immune checkpoint inhibitors compared to antiPD1 monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma (Mahdi) – currently open for safety lead in
 - **16/90 patients enrolled (25 for safety lead in)**
 - Safety call Friday 3:30 pm
 - Discuss eligibility criteria, review barriers to opening at phase I and all sites.
 - Measurable or evaluable disease; 0-2 prior lines (allowed to be chemo naïve)

Active Phase II Studies (including safety lead-ins):

- **EA191- N4:** A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial Shannon Westin, MD, MPH **18/165 enrolled**

Under Development

Endometrial cancer studies:

- **EAY191-N5** Phase II study of TKI and CDK4/6i in HER2+ (Mahdi)

Ovarian Cancer Studies (including safety lead-in):

- **DT/RT2321** Exportin 1 inhibitor, eltanexor, in patients with recurrent low-grade serous ovarian carcinoma; a phase II non randomized study. (Nasioudis/Simpkins)

Closed DT/Phase I studies:

Cervical Cancer Studies:

- **NRG-GY017** Anti PD-L1 (atezolizumab) as an immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer.
 - (Mayadev/ Schilder/Zamarin) Safety lead-in – completed. Study closed. Plenary at SGO 2022 and 2023
 - Manuscript status update

Endometrial Cancer Studies:

- **NRG-GY014**, A phase II study of tazemetostat (EPZ-6438) in recurrent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma (Ramez Eskander)
 - **Second stage amendment for ovarian clear cell cancer ARID1A mutant cohort. Reopened 2/7/22 and now closed to accrual**
- **NRG-GY012**, A Randomized Phase II Study Comparing Single Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. (Mackay/Bender/Rimel).
 - Completed DT safety review; uterine corpus committee

Ovarian Cancer Studies:

- **NRG-GY007** A phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (Landen) **Completed accrual**. Presented at ASCO 2022
- **NRG-GY009 (PTMA/CRDL)** A randomized, phase II/III study of pegylated liposomal doxorubicin and atezolizumab versus pegylated liposomal doxorubicin/bevacizumab and atezolizumab versus pegylated liposomal doxorubicin/bevacizumab in platinum resistant ovarian cancer (O'Cearbhaill)
 - **Phase II** completed accrual May 2019. Phase III completed accrual October 2021
 - IGCS 2023

- **NRG-GY021** A randomized phase II trial of olaparib versus olaparib + tremelimumab in platinum-sensitive recurrent ovarian cancer (Adams)
 - Safety lead-in closed March 2021, study permanently closed
 - Toxicity limited further enrollment and analyzing data, manuscript pending
 - CMAC is doing correlative studies and completed.

Session Title Developmental Therapeutics Radiation Therapy Subcommittee

Date February 12, 2024 Chair(s) Steven Lin, MD, PhD

Time 3:00-4:00pm Vice Chair(s) Sandip Patel, MD

Room Location Virtual

Learning Objectives

Following this activity, participants will be better able to:

1. Appraise the role of translational medicine in early clinical trials
2. Review the contributions of immune profiling in early clinical trials

Meeting Agenda

Time	Topic	Presenter
3:00pm	Introduction General Business	Steven Lin, MD, PhD
	Enhance Translational Studies in Early Clinical Trials for Cancer Therapy	Helen Chen, MD
	DTRT White Paper Update	Zachary Zumsteg, MD Siddarth Sheth, MD
	Disease Site and Working Group Updates	
	-GYN	Jyoti Mayadev, MD
	-Brain/CNS	Vinay Puduvalli, MD
	-Sarcoma Working Group	Meng Welliver, MD
	-Genitourinary	Zachary Zumsteg, MD
	-Head and Neck	
	-Breast	Steven Chmura, MD
	-Lung	Steven Lin, MD, PhD
	-GI Non-colorectal	Terence Williams, MD
	-GI Colorectal	Terence Williams, MD
	QUESTIONS / DISCUSSION	

Session Information

Session Title	Gastrointestinal Cancer Committee Workshop		
Date	February 17, 2024	Chair(s)	Thomas George, MD, FACP (Colorectal) Ted Hong, MD (Non-Colorectal)
Time	11:00am-12:30pm	Vice Chair(s)	Scott Kopetz, MD, PhD (Colorectal) David Ilson, MD (Non-Colorectal)
Room Location	Crystal G1		

Meeting Agenda

Time	Topic	Presenter
11:00-11:45am	CRC SUBCOMMITTEE – Review of Active and Select Upcoming NCTN Trials	
	<u>Adj. Colon</u> NRG-GI005 (COBRA): ctDNA as decision tool for stage II colon cancer treatment NRG-GI008 (CIRCULATE-NA): ctDNA as decision tool for stage III colon cancer treatment S0820 (PACES): Eflornithine & Sulindac for polyp prevention after CRC A022004: BRAF V600E (MSS) colon adjuvant consolidation with Encorafenib & Cetuximab vs. BSC A221805: Duloxetine as oxaliplatin neuropathy mitigation	Kyle Van Morris, MD Arvid Dasari, MD Jenny Dorth, MD Olatunji Alese, MD Jordan Kharofa, MD
	<u>mCRC</u> NRG-GI004/S1610 (COMMIT): MSI-H mCRC 1L Immunotherapy Study EA2222: Systemic therapy +/- HAI following 1L therapy A022101/NRG-GI009 (ERASur): Oligo mCRC Total Ablative Therapy	Caio Rocha Lima, MD Rimini Breakstone, MD Motaz Qadan, MD Paul Romesser, MD Kate Hitchcock, MD, PhD Eric Miller, MD, PhD
	<u>Rectal</u> EA2201: MSI-H rectal cancer Treatment w/ IO A022104/NRG-GI010 (JANUS): Watch & Wait vs. TME after optimal TNT	Prajnan Das, MD William Hall, MD Arvind Dasari, MD
11:45am-12:30pm	NON-CRC SUBCOMMITTEE – Review of Active Trials and Select Upcoming NCTN Trials	
	<u>Liver</u> Trial in Development: Atezo/Bev +/- SBRT NRG-GI003: Phase III RCT of Protons vs. Photons for HCC	Jennifer Wo, MD Ted Hong, MD
	<u>EGA</u> NRG-GI006: Phase III RCT of Protons vs. Photons for Esoph Carcinoma	Steven Lin, MD

NRG-GI007: Phase I w/ Expansion Cohort of OBP-301 (Telomelysin) and Definitive ChemoRT for non-operative locally adv EGA

Geoff Ku, MD

EA2183: Rand phase II evaluating consolidative radiation + IO during 1L systemic therapy in oligometastatic EGA

Kimberly Mak, MD

EA2174: Rand phase II study of peri-operative nivolumab and ipilimumab in EGA/GEJ

Evan Wuthrick, MD

Anal

EA2182: A Randomized Phase II Study of De-intensified ChemoRT for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Prajnan Das, MD

Panc

NRG-GI2319 (Trial in Development): A randomized phase II trial of dose escalated radiation in 5 or 15 fractions for LAPC

Nina Sanford, MD

Session Information

Session Title	GI Colorectal Cancer Subcommittee		
Date	February 17, 2024	Chair(s)	Thomas George, MD, FACP
Time	7:30 – 9:00am	Vice Chair(s)	Scott Kopetz, MD, PhD
Room Location	Magnolia 4-6		

Meeting Agenda

Time	Topic	Presenter
7:30am	Introductions and Opening Remarks	Thomas George, MD Scott Kopetz, MD, PhD
	Committee Structure and Working Group Functions	
	New Member and Early Career Investigator Introductions	Heloisa Soares, MD Evan Wuthrick, MD
	Updates from Committee Liaisons	
	Colon Cancer Working Group	Christina Wu, MD
	NRG-GI005 (COBRA): ctDNA as a decision tool for stage II colon cancer treatment	Kyle Van Morris, MD
	NRG-GI008 (CIRCULATE-US): ctDNA as a decision tool for stage III colon cancer treatment	Arvind Dasari, MD
	NRG-GI004/S1610 (COMMIT): MSI-H mCRC 1L Immunotherapy Study	Caio Rocha Lima, MD
	A022101/NRG-GI009 (ERASur): Oligo mCRC Total Ablative Therapy	Paul Romesser, MD Kate Hitchcock, MD, PhD Eric Miller, MD, PhD
	CONCEPT Update* NRG-CR2314 (Radio): Ablative Liver Met Radiation for IO Response in Microsatellite Stable (MSS) mCRC	Chris Anker, MD Aparna Parikh, MD
	CONCEPT Update* ctDNA for mCRC therapy determination	Vaia Florou, MD
	New CONCEPT* PREVAIL for MRD after curative mCRC liver resections	Scott Kopetz, MD, PhD Jon Loree, MD
	New CONCEPT* P-Mab-PD-PARPi for RAS WT mCRC	Olatunji B. Alese, MD
	Rectal Cancer Working Group	Kate Hitchcock, MD, PhD
	A022104/NRG-GI010 (JANUS): Watch & Wait vs. TIME after optimal TNT	William Hall, MD
	CONCEPT Update* SOLO – SCRT vs. LCRT in TNT	Glen Balch, MD, MBA
	NET Working Group	Heloisa Soares, MD
	Portfolio Update: NCTN Portfolio of active/upcoming NET trials	Heloisa Soares, MD

Session Title	Genitourinary Cancer Workshop		
Date	February 17, 2024	Chair(s)	Felix Feng, MD
Time	7:30 - 9:00am	Vice Chair(s)	Jason Efstathiou, MD; Todd Morgan, MD; Oliver Sartor, MD, Phuoc Tran MD PhD
Room Location	Crystal G1		

Learning Objectives

Following this activity, participants will be better able to:

1. Recognize critical aspects of developing and conducting a clinical trial in genitourinary (GU) cancer therapy research in a cooperative group setting.
2. Identify and describe the design and status of new GU cancer clinical trials being planned and launched by NRG Oncology, to enable contribution to protocol design vetting and/or effective patient enrollment in newly-launched studies.
3. Identify and describe the status of ongoing GU cancer clinical trials being conducted by NRG Oncology, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
4. Identify, describe, and analyze aspects of ongoing NRG Oncology GU clinical trials which are in need of special support and improvement, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
5. Identify and discuss the results and publication status of GU cancer clinical trials recently completed by NRG Oncology, so they can make informed decisions based on the state of the science regarding patient treatment, and they can relay study results to patients treated on these trials.
6. Identify and describe new forms of radiotherapy delivery and their use in NRG Oncology GU cancer trials.
7. Identify and describe systemic therapies, including chemotherapeutic drugs, hormonal strategies, biologic agents, and new classes of targeted therapies that may be used in conjunction with radiation therapy in GU cancer treatment, and the effectiveness of those agents as demonstrated in NRG Oncology clinical trials.
8. Identify and describe new developments in biologic and imaging science that can be used in translational research strategies to identify GU cancer patient subgroups at risk for failure with existing treatments and identify new approaches for these patients.

Meeting Agenda

Time	Topic	Presenter
7:30-7:35am	Opening Remarks and Update	
7:35-8:50am	Review of Active Trials	
	NRG-GU007: Phase I/IIR of RT + ADT +/- the PARP inhibitor Niraparib for patients with high-risk prostate cancer	Dror Michaelson, MD, PhD Zach Zumsteg, MD
	NRG-GU008: Androgen Deprivation Therapy With or Without Radiation Therapy or Docetaxel in Patients With Node-Positive Prostate Cancer: A Phase III Randomized Trial	Ronald Chen, MD, MPH
	NRG-GU009 (PREDICT-RT): Parallel Phase III Randomized Trials for High Risk Prostate Cancer Testing Treatment De-Intensification for Men with Lower Genomic Risk and Treatment Intensification for Men with High Genomic Risk	Paul Nguyen, MD Oliver Sartor, MD
	NRG-GU010 (GUIDANCE): Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-intensification and Intensification Clinical Trial	Neil Desai, MD Ale Berlin, MD, PhD
	NRG-GU011 (NRG PROMETHEAN): Phase II trial of PROstate oligoMETastatic radiotheraPy with or without ANDrogen deprivation therapy	Bridget Koontz, MD
	NRG-GU012 (SAMURAI): Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy	Bill Hall, MD Rana McKay, MD
	SWOG/NRG 1806: Chemoradiation +/- Immune Checkpoint Blockade for Bladder Cancer	Jason Efstathiou, MD
	SWOG 1802: Local therapy for M1 prostate cancer, a SWOG study	Brian Chapin, MD Richard Valicenti, MD
	EA8191: Phase III Study of Local or Systemic Therapy Intensification Directed in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE)	Neha Vapiwala, MD Bridget Koontz, MD
	NRG-GU013 (HIGH FIVE): Five fraction radiation for high-risk prostate cancer	Karen Hoffman, MD
8:50-8:55am	Other Issues	
	Translational Research	Phuoc Tran, MD, PhD
	Medical Oncology Update	Oliver Sartor, MD
	Urology Update	Todd Morgan, MD
	New Business	Group
8:55-9:00am	Closing Remarks	

Session Information

Session Title	Gynecologic Cancer Committee		
Date	February 17, 2024	Chair(s)	Carol Aghajanian, MD
Time	7:45-9:30am	Vice Chair(s)	Paul DiSilvestro, MD; David Gaffney, MD, PhD Heather Lankes, PhD, MPH (Translational)
Room Location	Sago		

Meeting Agenda

Topic

General Business

Call to Order
Symposia Updates

Committee Descriptions

Cervix/Vulva Cancer Subcommittee

Cervical Cancer: Randomized Phase II, Phase II/III, Phase III
Vulvar Cancer: Phase II, Randomized Phase II, Phase II/III, Phase III

Ovarian Cancer Subcommittee

Ovarian Cancer (Ovarian Cancer = Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer)
Neoadjuvant Chemotherapy (NACT) – Randomized Phase II
Randomized Phase II, Phase II/III, Phase III

Rare Tumor Subcommittee

Clear Cell Tumors
Germ Cell Tumors
Ovarian – Low Grade Serous
Ovarian – Mucinous
Ovarian – Stromal Tumors

Uterine Corpus Cancer Subcommittee

Endometrial Cancer
Randomized Phase II, Phase II/III, Phase III
Uterine Sarcoma (Leiomyosarcoma)
Randomized Phase II, Phase II/III, Phase III
Gestational Trophoblastic Neoplasm (GTN)

GYN Developmental Therapeutics Committee

Early Phase Trials (Phase I, Phase I/II, Phase II), Window of Opportunity Trials
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Uterine Sarcoma

GYN Phase I Subcommittee

Safety Lead-Ins
Phase I

Other NCTN Group Trials & Study Champions

A091903, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma (Alliance: Alexander N. Shoushtari, MD, NRG Oncology: Danielle Vicus, MD) Temporarily Closed to Accrual as of 10/10/2023

A092104, A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy (Alliance: Matthew Ingham, MD, NRG Oncology: Martee Hensley, MD)

AGCT1531, A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors. This is an Adolescent and Young Adult (AYA) Study: Available to COG and the Adult Groups
NRG Oncology Study Champion: Al Covens

AGCT1532, A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors. This is an Adolescent and Young Adult (AYA) Study: It is available to COG and the Adult Groups
NRG Oncology Study Champion: Al Covens

Small Cell Neuroendocrine, First line (NCTN, SWOG): S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
NRG Oncology Study Champion: Haider Mahdi

Cervix/Vulvar Cancer Subcommittee

New Concepts

CV2406, Phase III study of radiation with concurrent cisplatin/pembrolizumab* vs radiation with concurrent cisplatin/paclitaxel/pembrolizumab* for locally advanced cervical cancer *per FDA indication (Peter Rose, Suda Rani Amarnath)

CV2407, A Phase III Randomized Three Arm Trial of Concurrent chemoradiation or Pembrolizumab and concurrent chemoradiation or Induction Chemotherapy followed by concurrent chemoradiation in locally advanced cervical cancer (Jayanthi Lea, David Miller)

Studies Under Development

CV2305, STRIVE Study: STRatification of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision (Jessica McAlpine/Amy Jamieson: CCTG, Ritu Salani/Lillian Gien: NRG)

CV2332, A Phase I/II randomized non inferiority trial of hypofractionated IMRT with concurrent cisplatin and brachytherapy for cervical cancer versus conventional standard of care (Christina Henson)

CV2346, Chemoradiation with or without Checkpoint Inhibition in Lymph Node Positive Carcinoma of the Vulva (Scott Glaser)

CV2401, Neoadjuvant immunotherapy with chemotherapy followed chemoradiation and immunotherapy vs. chemoradiation and immunotherapy (Jyoti Mayadev/Dmitriy Zamarin)

Active Studies

NRG-GY024, Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Brian Slomovitz)

Closed Studies, primary manuscript NOT published (Cervix): RTOG-0724, GOG-0263, GOG-0279, NRG-GY006

Closed Studies, primary manuscript NOT published (DT): GY017

Closed studies, primary manuscript published (Outside Group): 270 (GROINSS-V), THE OUTBACK TRIAL (ANZGOG 0902/GOG 0274/RTOG 1174)

Ovarian Cancer Subcommittee

New Concepts

OV2412, Phase II Study of Adjuvant Trastuzumab Deruxtecan for HER2 Expressing High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSOC) after Suboptimal Response to Neoadjuvant Platinum-based Chemotherapy (Siddhartha Yadav, Andrea Hendrickson)

DT2413, Single Arm, Phase II Evaluation of Durvalumab and Tremelimumab for Recurrent or Metastatic Ovarian and Uterine Clear Cell Carcinoma with PPP2R1A Loss-of-function Mutations (Ken Lin, John Farley, Amir Jazaeri)

OV2414, GnRH (Elagolix) Antagonism in platinum-resistant ovarian cancer: a single-arm phase II trial (GREAT trial) (Adrienne Mallen, Jose Conejo-Garcia)

RT2415, A Phase II trial of Simvastatin and Pembrolizumab in Women with ARID1A-mutated Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum (John Farley)

Studies Under Development

NRG-GY034, A Randomized Phase 1/2 Trial Evaluating the Addition of ASTX660 (Tolnapant) to Weekly Paclitaxel with or Without Bevacizumab in Patients With Recurrent Platinum Resistant and Platinum Refractory Epithelial Ovarian Cancer (Kristen Zeligs)

NRG-GY035, Open Label, Multi-Center Phase 1/2 Study of Pegylated Liposomal Doxorubicin/Carboplatin/Eltanexor and Eltanexor maintenance versus Pegylated Liposomal Doxorubicin/Carboplatin/Bevacizumab and Bevacizumab maintenance in Patients with Platinum Sensitive Ovarian, Tubal, or Peritoneal Carcinoma who received a PARP inhibitor maintenance in a prior line of therapy (Rebecca Arend)

NRG-GY036, A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated Or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (Ying Liu)

RT2310, A Phase III Study of Fulvestrant with or without Abemaciclib in Patients with Recurrent Low-grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum (Lauren Cobb)

RT2339, A Phase II study of abemaciclib in combination with letrozole in patients with recurrent adult-type ovarian granulosa cell tumor (Lauren Cobb)

OV2348, The efficacy of 3 cycles of carboplatin and paclitaxel followed by maintenance Olaparib vs. 6 cycles of carboplatin and paclitaxel in I-IIIA high grade epithelial ovarian cancer (Mariam AlHilli, Elizabeth Swisher)

Active Studies

NRG-GY019, A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low Grade Serous Carcinoma of the Ovary or Peritoneum (Amanda Nickles Fader)

NRG-GY027, Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin with Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805 (Katherine Fuh)

NRG-GY031, A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer (Fiona Simpkins)

NRG-GY033, A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor (Elizabeth Hopp)

Closed Studies, primary manuscript NOT published (Ovarian): GY005, GY007, GY009, GY021, GY023

Closed Studies, primary manuscript NOT published (DT): GY014 Closed Studies, primary manuscript NOT published (Rare Tumor): 264, GY016

Closed Studies (primary manuscript published): 213, 262, GY003, GY004

Terminations: 212, 268, 283, GY029

Uterine Corpus Cancer Subcommittee

New Concepts

DT2408, A Phase II Study of Immunotherapy plus oral Selinexor as Maintenance Therapy in p53 Wildtype Advanced/Recurrent Endometrial Cancer (Bhavana Pothuri, Vicky Makker, Tarik Silk)

UC2409, A Phase II trial of Giredestrant with Abemaciclib in Patients with Advanced or Recurrent ER+ Leiomyosarcoma with CDKN2A deletion and intact RB1 (Sam Bose, Martee Hensley)

UC2410, A Phase II Randomized Trial of Adjuvant Gemcitabine/Docetaxel versus Doxorubicin/Trabectedin Chemotherapy in Uterine Leiomyosarcoma (Elise Haddad, Pamela Soliman)

UC2411, A Phase II/III Study Evaluating Endocrine Therapy compared to Chemotherapy as adjuvant therapy for patients with advanced stage NSMP Endometrial Cancer (Corr, Erickson, Eskander, Secord)

Studies Under Development

NRG-GY032, A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (Rainbo Blue & Taper) SUBSTUDY A: RAINBO POLEmut-BLUE: Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) TransPORTEC platform trials; SUBSTUDY B: Tailored Adjuvant Therapy in p53-Wildtype/NSMP Early Stage Endometrial Cancer (TAPER) CCTG Protocol Number: EN.10 (CCTG Study Co-Chairs: Kathy Han, Jessica McAlpine)

UC2230, Phase II Study of Single-Agent Pembrolizumab (anti PD-1) in Microsatellite Instability-High (MSI-H) Early-Stage Endometrial Cancer Patients (Elisabeth Spénard)

UC2323, Randomized phase III trial of carboplatin, paclitaxel, pembrolizumab, with or without bevacizumab in the treatment of primary, pMMR advanced stage (3 or 4) or recurrent endometrial cancer (Amanda Nickles Fader)

UC2108, Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Women with Advanced or Recurrent AR Positive ER Low Endometrial Cancer (Katherine Kurnit)

UC2229, Evaluating a Molecular based protocol for EaRly stage high-intermediate risk Endometrial carcinomas directed by ctDNA: The EMERGE-C Trial (Kuroki, Lee, Pothuri, Secord, Hacker)

UC2330, Gemcitabine-docetaxel followed by gemcitabine maintenance vs. Doxorubicin-trabectedin followed by trabectedin maintenance as first line treatment for metastatic uterine leiomyosarcoma (Martee Hensley)

Active Studies

NRG-GY025, A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (Haider Mahdi)

NRG-GY026, A phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (Britt Erickson)

NRG-GY028 (PTMA#100828), A Phase IB and Randomized Phase II Trial Of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer (Michaela Onstad Grinsfelder)

Closed Studies, primary manuscript NOT published (Corpus): 238, NRG-GY012 (Part 1 published), NRG-GY020

Closed Studies, primary manuscript NOT published (DT): 286B

Closed Studies (Primary manuscript published): 258, NRG-GY018

Terminations: 188

Developmental Therapeutics Committee

Studies Under Development

MATCH COMBO

EAY191-N5, A randomized trial of neratinib, a pan-ERBB inhibitor, alone or in combination with palbociclib, a CDK4/6 inhibitor, in patients with HER2+ gynecologic cancers and other solid tumors: A ComboMATCH Treatment Trial (Haider Mahdi)

Active Studies

NRG-GY022, Assessment of carboplatin clearance predictors: a companion PK study to NCI sponsored clinical trials or standard of care treatments using carboplatin (Sarah Taylor, Jan Beumer)

EAY191-N2, Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial (Bora Lim)

EAY191-N4, A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial (Shannon Westin)

Cancer Prevention and Control Committee Report

NCORP Studies:

Active Studies

NRG-CC008, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROC) (Kathryn Pennington, Warner Huh)

NRG-CC010, A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer (Edward Tanner)

Closed Studies:

GOG-278, Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (= $\leq$ 2CM) Cervical Cancer

Patient Reported Outcomes Research (PCOR) Committee Report

Translational Science Committee Report

Cancer Care Delivery Research Committee Report

Session Information

Session Title	Head and Neck Workshop		
Date	February 16, 2024	Chair(s)	Sue Yom, MD
Time	4:30-6:00pm	Vice Chair(s)	Erich Sturgis, MD, MPH; Stuart Wong, MD; Neil Hayes, MD
Room Location	Royal		

Meeting Agenda

Time	Topic	Presenter
4:30pm	Head and Neck Portfolio and Membership Update	Sue Yom, MD
	<u>Actively Developing Studies</u>	
	<u>RTOG 3521 TRANSPARENT</u> : Single-arm study of ToRipAlimab in combiNation with ciSPlatin and gemcitAbine in Recurrent mEtastatic Nasopharyngeal carcinoma systemic Treatment naïve participants	Anna Spreafico, MD
	<u>NRG-HN012 XCELSIOR</u> : Randomized phase II/III trial of radiation and Xevinapant vs. radiation and CETuximab in LA HNSCC patientsS with clsplatin cOntRaindication	Loren Mell, MD
	<u>NRG-HN014 (formerly NRG-HN2316)</u> : Phase II/II immunotherapy with response-adapted treatment vs. standard-of-care for resectable stage III/IV cutaneous squamous cell carcinoma	Neil Gross, MD
	<u>NRG-HN013 concept (SWOG leading)</u> : Ph II trial of cetuximab vs amivantamab in immunocompromised patients with recurrent inoperable or metastatic cSCC	Paul Swiecicki, MD
	<u>NRG-HN2405 concept (formerly HN2139)</u> : Randomized phase II trial of chemo-immunotherapy or immunotherapy in patients with recurrent/persistent PD-L1 enriched SCCHN undergoing salvage surgery	Nabil Saba, MD
	Fellowship Update	
	ECNI	Gary Lewis, MD
	Health Equity	Evan Graboyes, MD
	Patient Advocate Update	Jeffrey Shoop

<u>Review of Active Studies</u>	
Actively Accruing Trials RTOG 1216: RT+cisplatin vs. RT+cisplatin vs. RT+docetaxel +cetuximab vs. RT+cisplatin+atezolizumab for “high risk” resected HNSCC (Phase IIIR) NRG-HN006: Phase II-III SLN Biopsy vs. END in T1-2N0 oral cavity cancer NRG-HN008: Phase I RT + DNA-PK inhibitor in cisplatin-ineligible patients with high-risk LA HNSCC NRG-HN009: Phase II-IIIR RT with q3week cisplatin (100 mg/m ² x 3) vs q1week cisplatin (40 mg/m ² x 7) for locoregionally advanced HNSCC NRG-HN010: Phase IIR trial of docetaxel and HER2 targeted therapies in HER2+ recurrent/metastatic salivary duct/SGC NRG-HN011: Phase II Nivolumab vs Nivolumab+Relatlimab as Maintenance after First-line Platinum-Gemcitabine-Nivolumab in EBV Recurrent/Metastatic NPC (REMAIN) RTOG 3507: Phase IIR - ReRT +/- Pembrolizumab in Locoregionally recurrent HNSCC	Julie Bauman Paul Harari David Rosenthal Stephen Lai Maura Gillison Michael Samuels Paul Harari Alan Ho Brigitte Ma Stuart Wong
Report on Publications and Protocols Closed to Active Accrual	Sue Yom, MD
Working Group Update	Stuart Wong, MD
Early Career New Investigator Update	Shlomo Koyfman, MD
NRG Championed Trials Updates	Sue Yom, MD
NCI Head and Neck Steering Committee Update	Loren Mell, MD

Session Information

Session Title	Immunotherapy Subcommittee		
Date	February 13, 2024	Chair(s)	Susanna Ulahannan, MD
Time	3:00-4:00pm	Vice Chair(s)	Janice Lu, MD
Room Location	Virtual		

Meeting Agenda

Time	Topic	Presenter
3:00pm	Introduction of New Members	Dr. Ulahannan
	Approach to Concept/Protocol Review from the Immunotherapy Subcommittee Perspective	Dr. Doonan
	Discussion: Future Concept Ideas	
	Questions / Discussion	

Additional Notes:

Session Information

Session Title	International Members Subcommittee Meeting		
Date	February 15, 2024	Chair(s)	Ben Corn, MD and Keiichi Fujiwara, MD
Time	9:00 – 10:00am ET	Vice Chair(s)	
Room Location	Virtual / Magnolia 4-6		

Meeting Agenda

Time	Topic	Presenter
9:00 – 9:10am	Welcome and Opening Remarks	Ben Corn, MD Keiichi Fujiwara, MD
9:10 – 9:20am	NRG International Membership News	Karan Boparai
9:20 – 9:30am	QA and Audit Update	Mary Jo Antonelli
9:30 – 9:40am	NRG-HN014 Study Spotlight Randomized Phase III Trial of Perioperative Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma	Neil Gross, MD
9:40 – 9:45am	Open Protocols for International Participation	Kate Wiser
9:45 – 9:50am	Important Regulatory Reminders	Jess Marston
9:50 – 10:00am	Closing Remarks, Questions and Discussion	

Additional Notes:

Session Information

Session Title	Lung Committee General Session		
Date	February 17, 2023	Chair(s)	Jeffrey Bradley, MD
Time	9:15-11:00am	Vice Chair(s)	Jessica Donington, MD, PhD; Martin Edelman, MD
Room Location	Crystal G1		

Meeting Agenda

Time	Topic	Presenter
9:15am	Active Studies:	
	NRG-LU004: Phase I IO+ RT for PDL1 >50% Stage III pts.	Steven Lin (Bradley presenting)
	RTOG 3515 / PAC 4: SBRT +/- durva for medically-inoperable Stage I	Cliff Robinson
	SWOG S1914/NRG: SBRT +/- neoadjuvant atezo for Stage I	Charles Simone
	NRG-LU007: Phase II/III ES-SCLC; chemo + atezo +/- RT	Quynh-Nhu Nguyen
	NRG-CC009: SRS vs HA-WBRT for SCLC brain mets	Vinai Gondi
	NRG-LU008: Stage III using SBRT to primary; CRT to nodes	Charles Simone
	Champion Updates:	
	Lung-MAP SWOG S-1400	Sajama Waqar
	ALCHEMIST Trial	Sajama Waqar
	SWOG S1827 - Maverick trial comparing MRI vs PCI for SCLC	Daphna Gelblum
	QUESTIONS / DISCUSSION	

Session Title	Medical Oncology Committee		
Date	February 12, 2024	Chair(s)	Corey Langer, MD
Time	11am-1pm EST	Vice Chair(s)	Deborah Armstrong, MD
Room Location			

Session Information

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the uses of ctDNA across the oncology spectrum
2. Update disease-specific clinical trial outcomes and major advances from ASCO and ESMO 2023 and other critical meetings and presentations
3. Identify unique studies involving systemic therapy in the Medical Oncology sphere
4. ComboMatch update
5. Itemize the accomplishments of the Pharmacy and Immunotherapy Subcommittees and their bearing on protocol conduct

Meeting Agenda

Topic	Presenter
Introductions	Deborah Armstrong, MD
ComboMatch Update	Roisin O'Cearbhaill, MD
Pharmacy Subcommittee Update	Judith Smith, PharmD
Immunotherapy Subcommittee Update	Susanna Ulahannan, MD
CME presentation: ctDNA uses across the Oncology spectrum	Jenna Canzoniero, MD, MS
Select Disease Site Medical Oncology updates a. GYN b. HN c. Brain	Stephanie Gaillard, MD Jennifer Choe, MD, PhD Fabio Iwamoto, MD

Session Information

Session Title	NRG-BR008 Workshop		
Date	February 17, 2024	Chair(s)	Lior Braunstein, MD
Time	8:00-9:30am	Vice Chair(s)	
Room Location	Royal		

Meeting Agenda

Time	Topic	Presenter
8:00-8:05am	Welcome	Lior Z. Braunstein, MD
8:05-8:15am	NRG-BR008 Background and Protocol Overview	Lior Z. Braunstein, MD
8:15-8:30am	Protocol Eligibility and Treatment Information	Melissa Mitchell, MD
8:30-9:00am	Multidisciplinary Engagement for Patient Enrollment	Lior Z. Braunstein, MD Melissa Mitchell, MD
9:00-9:30am	Questions & Answers	

Session Information

Session Title	NRG-BR009 Workshop		
Date	February 16, 2024	Chair(s)	
Time	4:30-5:30pm	Vice Chair(s)	
Room Location	Magnolia 7		

Meeting Agenda

Time	Topic	Presenter
4:30-4:40pm	Welcome and NRG-BR009 Background	Eleftherios Mamounas, MD
4:40-4:50pm	NRG-BR009 Protocol Overview and Estradiol Measurement Issues	Sandra Swain, MD
4:50-5:00pm	NRG-BR009 Protocol Eligibility and Treatment Information	Shannon Puhalla, MD
5:00-5:15pm	NRG-BR009 Quality of Life and OFSET Registry	Patricia Ganz, MD
5:15-5:30pm	Questions & Answers and Discussion	

Session Title	NRG-CC011 Workshop		
Date	February 16, 2024	Chair(s)	Diane Von Ah, PhD, RN, FAAN
Time	8:30 – 10:00am	Vice Chair(s)	Patricia Ganz, MD; Brenna McDonald, MBA, PsyD, ABPP-CN
Room Location	Crystal J1		

Learning Objectives

Following this activity, participants will be better able to:

1. Identify the incidence, impact, and importance of cancer-related cognitive impairment for cancer survivors.
2. Describe the purpose and aims/objectives of the study protocol.
3. Identify the eligibility criteria for potential participants to include confirming criteria through a thorough medical record review and conducting the screening assessments as required for participation in the study protocol.
4. Implement the informed consent process with potential participants and complete all required documentation.
5. Identify and collect necessary information for stratification and complete the randomization of participants on the study.

Meeting Agenda

Time	Topic	Presenter
8:30-8:35am	Welcome, Introductions	Diane Von Ah, PhD
8:35-8:45am	Background: Incidence & Significance of Cancer-related Cognitive Impairment	Diane Von Ah, PhD
8:45-8:55am	Background: Interventions for Cancer-related Cognitive Impairment & Pilot data for Computerized Cognitive Training	Diane Von Ah, PhD
8:55-9:15am	Overview of the Study Protocol including Purpose, Aims/Objectives, Methods, Data Management & Analysis	Diane Von Ah, PhD
9:15-9:40am	Overview of Site-Specific Responsibilities	Diane Von Ah, PhD Tina Opoku
9:40-10:00am	Discussion of Frequently Asked Questions	Dianne Von Ah, PhD Patti Ganz, MD Hanna Bandos Tina Opoku

Session Title	NRG-CC012CD Workshop		
Date	February 16, 2024	Chair(s)	Alla Sikorskii, PhD
Time	2:00 – 3:00pm	Vice Chair(s)	Terry Badger, PhD; Tracy Crane, PhD
Room Location	Magnolia 7		

Learning Objectives

Following this activity, participants will be better able to:

1. Determine feasibility and fit of telephone-based monitoring of symptoms during oral anti-cancer treatment
2. Consider using automated telephone symptom management and telephone interpersonal counseling interventions to support patients during oral anti-cancer treatment
3. Understand procedures of CC012CD study for clinic personnel

Meeting Agenda

Time	Topic	Presenter
2:00-2:10pm	Welcome, Introductions	Tracy Crane, PhD
2:10-2:15pm	CC012CD Status Update	Tracy Crane, PhD
2:15-2:45pm	CC012CD Protocol Presentation	Grey Freylersthe Jamillah Gross-Caldwell
2:45-3:00pm	Questions, Discussion	

Session Information

Session Title	NRG Medical Physics Subcommittee Virtual Agenda		
Date	February 12, 2024	Chair(s)	Ying Xiao, PhD
Time	3:30 – 5:30pm	Vice Chair(s)	Stanley Benedict, PhD
Room Location	Virtual Only		
	3:00 pm – 3:30pm Virtual Only Joint Imaging and Medical Physics Seminar: Funding Opportunities for Integrated Imaging/Biomarker Investigations Lalitha Shankar, MD, PhD / Heather Jacene, MD		

Meeting Agenda

Time	Topic	Presenter
3:30 – 3:32pm	Topic Title (Welcome, Introductions) Subcommittee Updates	Ying Xiao, PhD Stanley Benedict, PhD
3:32 – 3:40pm	NCI/NCTN Updates - NCI Communications - NCTN Medical Physics	Ceferino Obcemea, PhD
3:40 – 3:50pm	NRG QA Report - IROC Houston - IROC Philadelphia RT (Contouring & Dosimetry) - IROC Philadelphia Imaging (reporting at Imaging)	Stephen Kry, PhD Ying Xiao, PhD Mark Rosen, MD
3:50 – 4:15pm	Disease Site Reports - Brain - Breast - GI - GU - GYN - H&N - Lung - NCORP	Yunfeng Cui / Fang-Fang Yin Guang-Pei Chen / Jean Moran William Parker/ Gemma Davies Mihaela Rosu Hayeon Kim / Cecilia Lee Nataliya Kovalchuk / Ping Xia Martha Matuszak / Timothy Ritter Yimei Huang / Tian Liu
4:15 – 4:25pm	Modality Technology Reports - Notable Technologies (Proton) - Proton SBRT	Xiaoying Liang Liyong Lin
4:25 – 4:58pm	Working Group and Other Updates	

	• Recommendations & Guidelines for Clinical Trials Involving Artificial Intelligence Assisted Automated Segmentation in Radiotherapy • AI for Radiotherapy Treatment Planning • FLASH • SFRT • Radiomics Phantom • Heart sub-structure	Sharon Qi / Yi Rong Xun Jia / Quan Chen Jennifer Zou Heng Li Jason Sohn Mihaela Rosu
4:58pm	Other Business: Questions/ General Discussions	
5:00pm	Adjournment	

Additional Notes:

Session Information

Session Title	NRG Oncology Health Disparities Committee		
Date	February 15, 2024	Chair(s)	Jennifer Wenzel, PhD, RN, CCM, FAAN Evan Graboyes, MD, MPH, FACS
Time	2:30-4:00pm	Vice Chair(s)	
Room Location	Crystal G1		

Meeting Agenda

Time	Topic	Presenter
2:30-2:40pm	Welcome/Announcements	Jennifer Wenzel, PhD, RN, CCM, FAAN Evan Graboyes, MD, MPH, FACS
2:40-2:50pm	Achieving Health Equity in HPV Positive Oropharyngeal Cancer Disparities	Tammara Watts, MD, PhD, FACS
2:50-3:05pm	Health Equity Fellow Experience – Q&A	Tara Castellano, MD
3:05-3:20pm	Older Adult Research	William Tew, MD
3:20-3:30pm	Rural Health Research Update	Na Tosha Gatson, MD, PhD, FAAN Shearwood McClelland, MD
3:30-3:40pm	Research Implementation (Education/Training/Mentorship) SIG	Victoria Bae-Jump, MD, PhD Mylin Torres, MD
	Clinical Trial Enrollment Updates – Statistics/Metrics – SDMC Reports	Mylin Torres, MD Reena Cecchini, PhD, MS
3:40-3:50pm	Research Concept Development HDC New Member Orientation HDC Liaisons	Evan Graboyes, MD, MPH, FACS
3:50-4:00pm	HDC Research Templates Consultation Recruitment and Retention	Jennifer Wenzel, PhD, RN, CCM, FAAN
	Closing Remarks	Jennifer Wenzel, PhD, RN, CCM, FAAN

Session Information

Session Title	NRG Oncology Imaging Committee		
Date	February 12, 2024	Chair(s)	Daniel Pryma MD
Time	1:30PM-3:30PM	Vice Chair(s)	Amy Fowler MD, PhD
Room Location	Virtual Only		

Meeting Agenda

Time	Topic	Presenter
1:30–1:35	Greetings	Amy Fowler MD, PhD
1:35-1:45	RPT Update	Ying Xiao, PhD
1:45-2:25	Disease site Updates since last meeting	
	▪ H&N	Cynthia Wu, MD Min Yao, MD
	▪ Brain	Tammy Benzinger, MD
	▪ Breast	Amy Fowler, MD, PhD
	▪ GYN	Karthik Sundaram, MD
	▪ GI	Aoife Kilcoyne, MD
	▪ GU	Ashesh Jani, MD Bill Hall, MD
	▪ Lung	Andrew Baschnagel, MD
2:25-2:30	Update from IROC PHL for NRG Trials	Mark Rosen, MD
2:30-2:45	NRG BN013 Central Imaging Review	Rupesh Kotecha, MD
2:45-3:00	NCORP CPC Concept 4DCT Functional Lung Avoidance to Decrease Radiation Induced Lung Injury.	Andrew Baschnagel, MD
3:00-3:30	NRG Imaging and Medical Physics Joint Seminar Funding Opportunities for Imaging Integrated/Biomarker Investigations	Lalitha Shankar, MD, PhD Heather Jacene, MD

Session Information

Session Title	NRG Oncology Radiation Oncology GYN Working Group		
Date	February 15, 2024	Chair(s)	Matthew Harkenrider, MD
Time	5:30PM-6:30PM	Vice Chair(s)	Diandra Ayala-Peacock, MD
Room Location	Magnolia 13-15		

Meeting Agenda

Time	Topic	Presenter
5:30-5:35	Scientific Developmental Focus A. Introductions / Announcements	Matthew Harkenrider, MD Diandra Ayala-Peacock, MD
5:35-5:40	B. History, Structure, and Mission Statement of RT GYN Working Group a. NRG Organizational Structure b. Working Group Goals/ Objectives i. Strategies for advancement of RT in GYN clinical trials c. Future Meeting Schedule • Hold 1 Zoom meeting between Winter and Summer NRG Oncology IN PERSON meetings. (July 12, 2024, and January 3, 2025) • July 25 -27, 2024 Sheraton Denver Downtown Hotel Denver, CO • January 16 -18, 2025 Phoenix Convention Center Phoenix, AZ	Matthew Harkenrider, MD Diandra Ayala-Peacock, MD
5:40-5:55	Educational Session: <i>Topic- TBD</i>	TBA
5:55-6:25	Discussion of New Concepts • Adaptive RT • Proton therapy	All
6:25-6:30	Concluding Remarks and Wrap-Up QUESTIONS / DISCUSSION	Matthew Harkenrider, MD Diandra Ayala-Peacock, MD

Session Information

Session Title	NRG Radiation Oncology Committee		
Date	February 16, 2024	Chair(s)	Evan Wuthrick, MD
Time	8:00 – 10:00 AM	Vice Chair(s)	Charles B. Simone II, MD
Room Location	Royal		

Meeting Agenda

Time (AM)	Topic	Presenter
8:00 – 8:05am	Welcome	Evan Wuthrick, MD
8:05 – 8:15am	NCI/NCTCN Updates • NCI Communications • NCTN Medical Physics	Ceferino Obcemea, PhD
8:15 – 8:25am	NRG RO Medical Physics Subcommittee	Ying Xiao, PhD
8:25 – 8:35am	NRG RO Particle Therapy Working Group	Charles Simone, MD
8:35 – 8:40am	NRG Imaging Committee - Dan Pryma /Amy Fowler	Dan Pryma, MD
8:40 – 9:00 am	Imaging and Radiation Oncology Core Group • IROC Houston • IROC Philadelphia • IROC Contouring and Dosimetry	Stephen Kry, PhD Densie Manfredi, BS Ying Xiao, PhD
9:00 – 9:50 am	Disease Site Reports – Updates on concepts near development a. H&N - Jimmy Caudell /Jason Chan b. Brain- Christina Tsien / Tony Wang c. Breast - Simona Shaitelman / Steven Chmura d. GYN- Eric Donnelly / Mark Bernard e. GI – William Hall / Kimberly Mak f. GU - Dan Krauss / Hiram Gay g. Lung - Stephen Chun MD /Pamela Samson h. Sarcoma - Philip Wong, MD / Dian Wang, MD	Jimmy Caudell, MD Christina Tsien, MD Steven Chmura, MD Eric Donnelly, MD William Hall, MD Dan Krauss, MD Pamela Samson, MD Philip Wong, MD
9:50- 10:00am	Questions	All

Session Information

Session Title	NRG Translational Science Breast Cancer Working Group Agenda		
Date	February 16, 2024	Chair(s)	Wendy Woodward, MD
Time	10:00 AM-12:00 PM	Vice Chair(s)	Vered Stearns, MD
Room Location	Magnolia 4-6		

Meeting Agenda

Time	Topic	Presenter
10:00-10:20am	NRG-BR009 Correlative Opportunities	Sandra Swain, MD
10:30-10:50am	Preoperative HER2+ Concept	Vered Stearns, MD
11:00-11:20am	NSABP B-64/Exact Sciences 2023-05 Overview	Mark Basik, MD Emilia Diego, MD
11:30-11:45am	Cardiac Risks After Contemporary Radiation	Julia White, MD
11:45am-12pm	Discussion, New Ideas	All
	Time Permitting: Navigator Overview	

Session Title	Ovarian Workshop		
Date	February 16, 2024	Chair(s)	Kathleen Moore, MD, MS
Time	1:00 – 3:00pm	Vice Chair(s)	Joyce Liu, MD, MPH; Elizabeth Swisher, MD; Rebecca Arend, MD
Room Location	Sago		

Learning Objectives

Following this activity, participants will be better able to:

1. Review the status of completed and ongoing NRG/GOG clinical trials on the treatment of ovarian cancer
2. Review the status of approved NRG/GOG concepts that are under development
3. Apply standard and review procedures required to design, submit, and conduct a research protocol within NRG, including ancillary data proposals
4. Assure strict quality control of NRG/GOG clinical trials

Meeting Agenda

Topic

Introduction

Review of learning objectives
Statements regarding potential conflicts of interest
Committee membership updates

Educational Talk

NIH Initiatives in Women's Health
Sarah Temkin, MD
Associate Director for Clinical Research, NIH Office of Research on Women's Health (ORWH)

Study Presentations

NRG-GY023: A randomized phase 2 trial of durvalumab/olaparib/cediranib vs. olaparib/cediranib vs. durvalumab/cediranib vs. physician choice chemotherapy in platinum-resistant ovarian cancer. **Jung-min Lee, MD, National Cancer Institute**

NRG-GY009: A randomized phase 2/3 study of PLD/atezolizumab vs PLD/bevacizumab/atezolizumab vs PLD/bevacizumab in platinum-resistant ovarian cancer. **Roisin O'Cearbhaill, MD, Memorial Sloan Kettering Cancer Center**

Review of Closed Studies (not terminated) – Status updates since July 2023 meeting in [blue](#).

GOG-0213: A phase III randomized controlled clinical trial of carboplatin and paclitaxel (or gemcitabine) alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian peritoneal primary and fallopian tube cancer (Robert Coleman)

-Lancet Oncol 2017
-NEJM 2019

GOG-0262: A randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without concurrent and consolidation bevacizumab in the treatment of primary stage III or IV epithelial ovarian, peritoneal or fallopian tube cancer (John K Chan)

-NEJM 2016

GOG-0273: Chemotherapy toxicity in elderly women with ovarian, primary peritoneal, or fallopian tube cancer (Vivian E von Gruenigen)

-Modified dose dense cohort manuscript in draft form

NRG-GY003: Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (Zamarin)

-J Clin Oncol 2020

GOG-0281: RP2/3 study to assess efficacy of Trametinib in recurrent or progressive low grade serous ovarian or peritoneal cancer. (David Gershenson)

-Presented IGCS 2019

-Lancet 2022

GOG-0264: RP2 trial paclitaxel-carboplatin vs BEP for newly diagnosed advanced stage and recurrent chemo-naïve sex cord stromal tumors of the ovary (Jubilee Brown)

-Presented IGCS 2020

-Draft in circulation

NRG-GY004: Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Joyce Liu and Ursula Matulonis)

-Presented ASCO 2020

-J Clin Oncol 2022

-OS data presented at ESMO 2023

NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-line Neoadjuvant and Post-surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary peritoneal Cancer. (Chip Landen)

-Presented ASCO 2022

-Manuscript submitted JCO

NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer (Roisin O’Cearbhaill, Carol Aghajanian)

-Presented IGCS 2023

NRG-GY023: A randomized phase II trial of triplet therapy (a PD-L1 inhibitor durvalumab in combination with olaparib and cediranib) vs. doublet therapy (olaparib and cediranib) vs doublet therapy (durvalumab and cediranib) vs physician choice chemotherapy in women with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal or fallopian cancer who have received prior bevacizumab (Jung-min Lee)

-Presented ESMO 2023

Review of Active Studies (all metrics are as of 01/2024) – Status updates since July 2023 meeting in [blue](#).

NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Jung-Min Lee and Angeles Alvarez Secord)

-Closed to accrual 10/02/2020

-Total accrual 562

NRG-GY014 (DT1718): A Phase II study of tazemetostat (EPZ-64438), an EZH2 inhibitor, in select gynecologic cancers (NCI CRDL LOI request). Limited sample size (n = 31), but requires genomics screening. (Ramez Eskander and David Hyman)

-Closed to accrual 06/15/2022

-Total accrual 62

NRG-GY019 (RT1753): A Phase III Randomized Three Arm trial of paclitaxel/carboplatin compared to paclitaxel /carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum. (Amanda Nickles-Fader)

-Activated 8/26/19

-303/457

NRG-GY021: Randomized Phase II Trial of olaparib + tremelimumab vs olaparib in platinum sensitive recurrent ovarian cancer/HRD+ and HRD. (Sarah Adams)

-Closed to accrual 10/19/2020

NRG-GY022 (DT1833): Assessment of carboplatin clearance predictors: PK protocol to allow for extra sample collection and collection of demographic data, laboratory values, and outcome data. (Liz Villaruz/Jan Beumer)

-Activated 11/2019

-261/350

-Now enrolling male pts only

NRG-CC008 (CC1923)(NC1427)(CPC1206): A non-randomized prospective clinical trial comparing the noninferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROCK) (Walker/Huh/Pennington)

-Activated 6/2020

-494/2262

-Allows surgery by non-NCTN/NCORP surgeons

AGCT1531 (RT1205): Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors (MaGIC, COG primary, AI Covens NRG)

-Activated 5/2017

-905/2059

NRG-GY027: A Phase IB Trial of Ipatasertib plus paclitaxel and carboplatin in women undergoing neoadjuvant chemotherapy for treatment naïve, epithelial ovarian cancer (Katherine Fuh/Kathleen Moore)

-Activated 6/27/2022

-12/24

-Temporary closure

-12 patient expansion planned

NRG-GY031 (DT2106): A Phase IB study of combination BET protein inhibition (ZEN3694) and ATR kinase (M1774) for the treatment of recurrent ARID1A mutated clear cell and endometrioid ovarian carcinomas (Yasuto Kinose/Fiona Simpkins)

-RSC 07/2021

-LOI approved 6/21/22

-Activated 08/31/23

-2/57

NRG-GY033 (RT2141): Phase II study of androgen receptor (AR) inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent AR positive adult-type ovarian granulosa cell tumor (Elizabeth Hopp/Janet Rader)

-RSC 05/2022

-LOI approved 1/10/24

-Activated 01/22/24

Review of Approved Concepts under Development -- status updates since July 2023 meeting in [blue](#).

NRG-GY034 OV2206: Randomized Phase 1/2 trial evaluating the addition of tolinapant to weekly paclitaxel with or without bevacizumab in patients with recurrent epithelial ovarian cancer (Zeligs/Annunziata)

-OTF 05/2022

-Revision to tolinapant reviewed at OTF 07/2022

-RSC 10/2022

-GCSC 11/16/2022

- CTEP approval 03/27/23.
- Protocol development in process.

NRG-GY035 OV2238: Open label, multi-center Phase 1/2 study of PLD / Carboplatin +/- eltanexor in patients with platinum sensitive ovarian, tubal, peritoneal carcinoma who have previously received a prior PARP inhibitor for maintenance (Arend/Moore)

- OTF 12/16/22, 03/31/23
- GCSC Approval on Hold 10/27/23
- Awaiting industry partner approval

NRG-036 OV2307: One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous

- OTF 03/17/23
- RSC 05/10/23

Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy (Ying Liu/Aghajanian)

- CTEP approval 11/01/23.
- Protocol development in process

Review of Concepts for Secondary Review

DT2413 Single Arm, Phase II Evaluation of Durvalumab and Tremelimumab for Recurrent or Metastatic Ovarian and Uterine Clear Cell Carcinoma with PPP2R1A Loss-of-function Mutations. Replaces DT2347 (Ken Lin, John Farley, Amir Jazaeri) DT, OV, UC, GYN **Review/vote will be conducted separately.**

QUESTIONS / DISCUSSION

Session Information

Session Title	Particle Therapy Working Group		
Date	February 16, 2024	Chair(s)	Charles B. Simone II, MD
Time	10:15 – 11:45am	Vice Chair(s)	N/A
Room Location	Royal		

Meeting Agenda

Time (AM)	Topic	Presenter
10:15 – 10:20	Welcome Address	Charles Simone, MD
10:20: 10:50	Symposium Theme: “Overcoming Obstacles to Enrollment on Proton Therapy NRG Oncology Trials” Moderator: Charles B. Simone II, MD	
	Talk 1 (8min): Patient barriers: Engaging patients and enhancing their willingness to participate.	Kristin Higgins, MD
	Talk 2 (8min): Provider barriers: Patient selection and enrollment equipoise.	Steven Lin, MD
	Talk 3 (8min): Enrollment challenges: Addressing insurance obstacles and designing pragmatic clinical trials. Q & A (6min)	Nancy Mendenhall, MD
10:50 – 11:00	Update from NCI	Jeff Buchsbaum, MD
11:00 – 11:05	Update on Proton Center Credentialing by IROC	Paige Taylor, PhD
11:05 – 11:10	Update on Medical Physics Proton	Xiaoying Liang, PhD
11:10 – 11:15	GU Studies: GU008, GU009 and GU010	Curtiland Deville, MD
11:15 – 11:20	GI Studies: • GI003 • GI006	Ted Hong, MD Steven Lin, MD, PhD
11:20 – 11:25	Brain Studies: BN001, BN003 and BN005	Minesh Mehta
11:25 – 11:30	Lung Studies: NRG/ROG 1308, LU006 and LU008	Charles Simone, MD
11:30 – 11:35	H&N Studies: HN009	Charles Simone, MD
11:35 – 11:40	Breast: RADCOMP RTOG 3510	Elizabeth Nichols, MD

Session Title	Patient Centered Outcomes Research (PCOR) Workshop Agenda		
Date	February 15, 2024	Chair(s)	
Time	4:00 – 6:00pm	Vice Chair(s)	Ben Movsas, MD; Ron Chen, MD
Room Location	Magnolia 20-21		

Learning Objectives

Following this activity, participants will be better able to:

1. Understand the role and responsibilities of being an PRO Co-chair for an NRG Oncology study.
2. Understand the importance of PRO compliance and data completeness.
3. Apply criteria for inclusion of PROs in NCTN Phase II and III clinical trials.

Meeting Agenda

Time	Topic	Presenter
4:00-4:05pm	Welcome and Session Introduction	Ben Movsas, MD
4:05-5:00pm	PRO Primer Workshop Q&A	Ben Movsas, MD Ron Chen, MD Stephanie Pugh, PhD
5:00-5:15pm	PRO and QOL Data Compliance Update	Marcie Ritter, PhD Kandie Dempsey, DBA, MS, RN, OCN
5:15-5:30pm	Developing Concepts/Protocols	Ben Movsas, MD Ron Chen, MD
5:30-5:40pm	Closing Remarks	Ben Movsas, MD Ron Chen, MD

Session Title	Pharmacy Subcommittee		
Date	February 13, 2024	Chair(s)	Judith A. Smith, BS, PharmD, BCOP, CPHQ
Time	11:00am-12:30pm	Vice Chair(s)	
Room Location	Virtual		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the supportive care resources available to investigators for management of common toxicities associated with chemotherapy.
2. Recognize the benefits of pharmacy review on NRG Oncology research protocols
3. Understand the rationale and benefits of standardizing drug information for research protocols.
4. Review the recent updates in monitoring for patients receiving chemotherapy associated with risk for cardiotoxicity.

Meeting Agenda

Time	Topic	Presenter
11:00-11:05am	Introductions	
11:05-11:35am	CME Lecture: “Cardioprotective Strategies in Patients Receiving Cardiotoxic Chemotherapy”	Rodney J. Hunter, PharmD, BCOP
11:35-11:45am	NRG Committee Pharmacy Liaison Updates Interim meeting updates	
11:45-11:50am	Update from Cooperative Group Pharmacy Leadership Collaboration	
11:50am-12:05pm	Practice Recommendation Documents Current Topics: Pharmacogenomic Drug Interactions (Pamala Pawloski) Skin Toxicities Hyperphosphatemia New Topics to Consider: Hypothyroidism/Hyperthyroidism monitoring and management	
12:05-12:10pm	Discussion to address drug shortages on clinical trials Communication and preemptive planning Revisit proposed language	
12:10-12:15pm	PMB Updates	Kayla Dye, PharmD
12:15-12:25pm	NRG Oncology Updates Membership recruitment area we need covered	
	QUESTIONS / DISCUSSION	

Session Title	Rare Tumor Subcommittee		
Date	February 15, 2024	Chair(s)	AI Covens, MD
Time	2:00 – 4:00pm	Vice Chair(s)	Jubilee Brown, MD
Room Location	Crystal H		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss past, ongoing, and emerging NRG clinical trials in rare gynecologic cancers
2. Discuss priorities and promising preclinical and translational objectives for future clinical trials
3. Discuss strategies to increase the portfolio of clinical trials in rare gynecologic cancers
4. Discuss potential collaborative Research Initiatives

Meeting Agenda

Time	Topic	Presenter
2:00-4:00pm	Welcome, Introductions: Welcome New Members	Committee Leadership
	Review of Active Studies	AI Covens, MD
	Studies Previously Approved in Development	AI Covens, MD
	New Concepts	
	SGO Bridges Update	Amanda Nickles-Fader, MD
	Updates from LGSO, CCO, and Stromal Tumour Groups	Amanda Nickles-Fader, MD John Farley, MD Jubilee Brown, MD

Session Information

Session Title	Sarcoma Working Group		
Date	February 16, 2024	Chair(s)	Dian Wang, MD, PhD
Time	10:00 am – 12:00 pm	TRP Liaison	Peter Houghton, PhD
Room Location	Magnolia 7		

Meeting Agenda

Topic	Presenter
Active Study: Phase I/II Trial of Preoperative Intensity Modulated Radiation Therapy (IMRT) for Retroperitoneal Sarcoma using a Simultaneous Integrated Boost (DeLaney/Yen-Lin Chen)	Yen-Lin Evelyn Chen, MD
New Concept: Phase II Study of Neoadjuvant Chemoradiation plus Immunotherapy for Angiosarcoma (Parul Barry and Brian Van Tine)	Parul Barry, MD
New Concept: Phase I Study on SBRT and Anlotinib in Relapsed/Refractory NRSTS (Susan Hiniker PI (COG) and Phil Wong Co-PI (NRG))	Phil Wong, MD
Sarcoma TRP: Development of effective therapies for soft tissue sarcoma	Raushan Kurmasheva, MD and Peter Houghton, PhD
Sarcoma TRP: Update on the chordoma contouring project	Phil Wong, MD
New Business	All

Additional Notes:

Projects “On Hold” are not noted on the agenda

Session Information

Session Title	Translational Science Brain Cancer Working Group		
Date	February 17, 2024	Chair(s)	
Time	10:00am-12:00pm	Vice Chair(s)	
Room Location	Crystal J1		

Meeting Agenda

Time	Topic	Presenter
10:00-10:05am	Introduction	Arnab Chakravarti, MD
10:05-10:35am	Updates on Radiation Oncology/Data Science Projects	Aline Becker, MD, PhD
10:35-11:05am	Synthetic Lethal Dependencies in MMR-Deficient (TMZ-Resistant) Gliomas	Sangita Pal, PhD
11:05-11:35am	Project Updates	Arnab Chakravarti, MD
11:35am-12:00pm	Round Table Discussion	

Session Title	Translational Science GYN		
Date	February 16, 2024	Chair(s)	Michael Birrer, MD, PhD
Time	4:30 – 6:00pm	Vice Chair(s)	Heather Lankes, PhD, MPH
Room Location	Virtual Only		

Learning Objectives

Following this activity, participants will be better able to:

1. Understand GYN translational science conducted by NRG and discuss GYN translational science projects.
2. Understand the organization and operations of the NRG Biospecimen Bank.
3. Understand the NRG biospecimen access process.
4. Assure strict quality control of NRG clinical trials, including GYN translational science.

Meeting Agenda

Time	Topic	Presenter
4:30-4:35pm	Welcome and Opening Remarks	Michael Birrer, MD, PhD Heather Lankes, PhD, MPH
4:35-4:40pm	Uterine Corpus Subcommittee	Vickie Bae-Jump, MD, PhD Katherine Fuh, MD, PhD
4:40-4:55pm	NRG-GY012: Translational study update from NRG-GY012	Helen MacKay, MD
4:55-5:00pm	Cervix/Vulva Subcommittee	Dmitriy Zamarin, MD, PhD
5:00-5:05pm	Ovarian Subcommittee	Rebecca Arend, MD Elizabeth Swisher, MD
5:05-5:10pm	Rare Tumor Subcommittee	Gloria Huang, MD
5:10-5:15pm	Developmental Therapeutics	Panagiotis Konstantinopoulos, MD, PhD
5:15-5:30pm	Genomic and molecular characterization of biomarkers associated with self-reported race/ethnicity in high-risk endometrial cancers from NRG Oncology/GOG Protocol 210, Molecular Staging of Endometrial Cancer	Case Cosgrove, MD
5:30-5:45pm	Genomic and molecular characterization of biomarkers associated with tumor angiogenesis, DNA repair, and immunologic tolerance among exceptional responders and long-term survivors in NRG Oncology/Gynecologic Oncology Group protocol 240	Krish Tewari, MD
5:45-5:50pm	Route 66 SPORE	Doris Benbrook, PhD
5:50-6:00pm	Discussion and closing remarks	Michael Birrer, MD, PhD Heather Lankes, PhD, MPH

Session Information

Session Title	Translational Science Head & Neck Cancer		
Date	February 16, 2024	Chair(s)	Neil Hayes, MD, MS, MPH
Time	2:00-3:00pm	Vice Chair(s)	
Room Location	Crystal J1		

Meeting Agenda

Time	Topic	Presenter
2:00-2:05pm	Introduction	Neil Hayes, MD, MS, MPH
2:05-2:30pm	Immunobiology of HPV Related OPC and Implications on Therapeutic Strategies	Nabil F. Saba, MD, FACP
2:30-2:55pm	Deconstructing Tumoral Heterogeneity: Investigating Head and Neck Cancer Stem Cell Plasticity	Steven Chinn, MD, MPH
2:55-3:00pm	Closing Remarks and Discussion	Neil Hayes, MD, MS, MPH

Session Information

Session Title	Translational Science Lung Cancer		
Date	February 16, 2023	Chair(s)	Bo Lu, MD
Time	10:00am-12:00pm	Vice Chair(s)	
Room Location	Crystal J1		

Meeting Agenda

Time	Topic	Presenter
10:00-10:24am	Opportunities for Plasma Proteomics in Lung Cancer Research	Adam Dicker, MD, PhD
10:24-10:48am	Pre-Treatment Circulating Cytokine Levels and Outcomes in NSCLC: Translational Analysis of NRG-RT0G 0617	Mitch Machtay, MD
10:48-11:12am	The Potential of 89Zr Crefmirlimab Berdoxam (CD8 ImmunImmunoPET™) Imaging in Radiation Oncology	Kristin Schmiedehausen, MD
11:12-11:36am	Electrocardiogram with Artificial Intelligence Assessment as a Predictive Tool for Cardiotoxicity and Overall Survival after Radiotherapy for Esophageal Cancer	Roman Kowalchuk, MD
11:36am-12:00pm	Utilizing Radiopathomics as a Potential Biomarker for Efficacy of Immunotherapy in Small Cell Lung Cancer	Kristin Higgins, MD

Session Title	Uterine Corpus Cancer Subcommittee		
Date	February 16, 2024	Chair(s)	Matthew Powell, MD; Ann Klopp, MD
Time	10:00am -12:00pm	Vice Chair(s)	Martee Hensley, MD; Katherine Fuh, MD, PhD; Victoria Bae-Jump, MD, PhD
Room Location	Sago		

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss national and international priorities, goals and initiatives in the management of Uterine cancer.
2. Discuss currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of uterine corpus cancers.
3. Discuss promising therapeutics in development and potential translational research objectives and strategies for future clinical trials.
4. Apply standards and procedures needed to design, submit, (revise), and conduct a research protocol within the NRG
5. Outline both potential barriers and potential solutions to improve enrollment to NRG clinical trials in uterine corpus cancers to include international collaboration

Meeting Agenda

Time	Topic	Presenter
10:00-10:10am	Welcome, Introductions	Matthew Powell, MD Ann Klopp, MD
10:10-10:20am	Update on recent NCI Endometrial Cancer CTM	Linda Duska, MD
10:20-11:10am	New Concepts	
11:10-11:30am	Review of open and recently closed trials	H. MacKay, R. Eskander, F. Backes, M. Powell, B. Erickson, L. Kuroki, C. Cosgrove
11:30-11:55am	Review of studies in development	V. Makker, A. Fader, A. Secord, A. Klopp
11:55am-12:00pm	Additional discussion / Question	



10 Years
NRG
ONCOLOGY
2024 WINTER MEETING

NRG Oncology

Institutional Accrual

Accrual For Agenda Book from 7/1/2023 to 12/31/2023 Run Date: 1/11/2024				
NRG Main Member (Network)	CTEP ID	Accrued to NRG	Accrued to Non-NRG	Total
Allan Blair Cancer Centre	11076	2	0	2
Allegheny General Hospital	PA009	5	1	6
Arizona Center for Cancer Care-Peoria	AZ127	0	0	0
Ascension Alexian Brothers - Elk Grove Village	IL280	0	0	0
Aurora NCI Community Oncology Research Program	AURORA	12	42	54
Avera Cancer Institute	SD021	3	12	15
Banner University Medical Center - Tucson	AZ017	8	1	9
Baptist Health Cancer Research Network	BHCRN	1	14	15
Baptist MD Anderson Cancer Center	FL003	0	3	3
Bay Area Tumor Institute NCORP	BATI	0	1	1
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	TX041	0	0	0
Baystate Medical Center	MA004	3	4	7
BCCA-Vancouver Cancer Centre	11081	0	0	0
Berkshire Medical Center - Cancer Center	MA125	0	0	0
Boston Medical Center	MA043	0	2	2
Cancer Research Consortium of West Michigan NCORP	CRCWM	25	1	26
Cancer Research for the Ozarks NCORP	OZARKS	5	0	5
Cancer Research of Wisconsin and Northern Michigan Consortium	CROWN	42	2	44
Cancer Trials Ireland	ICORG	0	0	0
Carle Cancer Center NCI Community Oncology Research Program	CARLE	6	0	6
Carolinas Medical Center/Levine Cancer Institute	NC042	21	0	21
Cedars-Sinai Medical Center	CA016	14	2	16
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont	11065	9	0	9
Chinese University of Hong Kong-Prince of Wales Hospital	34003	0	0	0
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)	11073	4	0	4
CHUM - Centre Hospitalier de l'Universite de Montreal	11062	0	0	0
City of Hope Comprehensive Cancer Center	CA043	15	1	16
CIUSSEMTL-Hopital Maisonneuve-Rosemont	11060	0	0	0
Columbia University Minority Underserved NCORP	COLUMBIA	2	10	12

Columbus NCI Community Oncology Research Program	COLUMBUS	1	0	1
CommonSpirit Health Research Institute	CORA	7	2	9
Community Cancer Center North	IN006	0	1	1
Cooper Hospital University Medical Center	NJ036	7	2	9
Covenant Medical Center-Lakeside	TX054	0	0	0
Cross Cancer Institute	11132	0	0	0
CWRU Case Comprehensive Cancer Center LAPS	LAPS-OH029	52	15	67
Dana-Farber / Partners CancerCare LAPS	LAPS-MA036	19	7	26
Danbury Hospital	CT030	0	17	17
Dartmouth College - Dartmouth Cancer Center LAPS	LAPS-NH012	28	2	30
Dayton NCI Community Oncology Research Program	DAYTON	1	0	1
Delaware/Christiana Care NCI Community Oncology Research Program	CHRISTIANA	12	0	12
Dell Seton Medical Center at The University of Texas	TX063	0	0	0
Duke University - Duke Cancer Institute LAPS	LAPS-NC010	19	1	20
Edward Hospital/Cancer Center	IL104	12	5	17
Emory University - Winship Cancer Institute LAPS	LAPS-GA005	18	5	23
Essentia Health NCI Community Oncology Research Program	ESSENTIA	5	4	9
Fox Chase Cancer Center	PA086	14	13	27
Fred Hutchinson Cancer Research Center LAPS	LAPS-WA008	14	1	15
Froedtert and the Medical College of Wisconsin LAPS	LAPS-WI013	17	0	17
Geisinger Cancer Institute NCI Community Oncology Research Program	GEISINGER	7	0	7
Georgia Cares Minority Underserved NCORP	GACARES	7	1	8
Georgia NCI Community Oncology Research Program	GEORGIA	8	7	15
Greater Baltimore Medical Center	MD018	1	8	9
Gulf South Minority Underserved NCORP	GULFSOUTH	14	0	14
Hackensack University Medical Center	NJ022	1	0	1
Hartford Hospital	CT009	3	11	14
Hawaii Minority Underserved NCORP	HAWAII	4	20	24
Heartland Cancer Research NCORP	HEARTLAND	20	1	21
Henry Ford Hospital	MI026	15	1	16
Houston Methodist Hospital	TX036	8	0	8
Indiana University/Melvin and Bren Simon Cancer Center	IN007	7	2	9

Intermountain Medical Center	UT056	0	5	5
Iowa-Wide Oncology Research Coalition NCORP	IWORC	9	14	23
James A. Haley Veterans Affairs Hospital	FL064	0	0	0
Jewish General Hospital	11116	0	0	0
JHU Sidney Kimmel Comprehensive Cancer Center LAPS	LAPS-MD017	6	6	12
Juravinski Cancer Centre at Hamilton Health Sciences	11183	0	0	0
Kaiser Permanente NCI Community Oncology Research Program	KAISER	296	18	314
Kaiser Permanente-Gaithersburg Medical Center	MD198	5	8	13
Kantonsspital Aarau	67029	0	0	0
Lahey Hospital and Medical Center	MA017	0	0	0
Lankenau Medical Center	PA125	0	0	0
Laura and Isaac Perlmutter Cancer Center at NYU Langone	NY011	20	1	21
Legacy Good Samaritan Hospital and Medical Center	OR013	5	0	5
Loyola University Medical Center	IL017	10	2	12
MaineHealth Cancer Care Network	MAINE	10	5	15
Mayo Clinic LAPS	LAPS-MN026	15	0	15
Medical University of South Carolina Minority Underserved NCORP	MUSC	11	7	18
MedStar Franklin Square Medical Center/Weinberg Cancer Institute	MD029	1	9	10
Memorial Sloan-Kettering Cancer Center LAPS	LAPS-NY016	35	4	39
Metro Minnesota Community Oncology Research Consortium	METROMIN	58	6	64
Miami Cancer Institute	FL078	7	8	15
Miami Valley Hospital	OH084	4	3	7
Michigan Cancer Research Consortium NCORP	MCRC	17	0	17
Michigan Healthcare Professionals Farmington	MI310	1	0	1
Michigan State University Clinical Center	MI038	0	0	0
Midwestern Regional Medical Center	IL120	1	2	3
Moffitt Cancer Center	FL065	8	8	16
Montana Cancer Consortium NCORP	MONTANA	5	0	5
Montefiore Minority Underserved NCORP	MONTEFIORE	5	4	9
Mount Sinai Hospital	NY021	7	2	9
National Cancer Centre Singapore	47005	1	0	1
National Institutes of Health Clinical Center	MD004	0	0	0

NCORP of the Carolinas (Prisma Health NCORP)	GREENVILLE	1	48	49
Nebraska Methodist Hospital	NE007	2	12	14
Nevada Cancer Research Foundation NCORP	NCRF	0	0	0
New Mexico Minority Underserved NCORP	NEWMEXICO	21	7	28
New York-Presbyterian/Brooklyn Methodist Hospital	NY075	22	0	22
NorthShore University HealthSystem-Evanston Hospital	IL018	4	0	4
Northwell Health NCORP	NORTHWELL	5	7	12
Northwestern University LAPS	LAPS-IL036	8	0	8
Norton Hospital Pavilion and Medical Campus	KY049	3	0	3
Odette Cancer Centre- Sunnybrook Health Sciences Centre	11118	5	0	5
Ohio State University Comprehensive Cancer Center LAPS	LAPS-OH007	31	2	33
Orlando Health Cancer Institute	FL020	1	0	1
Ottawa Hospital and Cancer Center-General Campus	11025	11	0	11
Pacific Cancer Research Consortium NCORP	PCRC	15	1	16
Parkview Regional Medical Center	IN181	4	2	6
Penn State Milton S Hershey Medical Center	PA042	10	2	12
Peter MacCallum Cancer Centre	3003	0	0	0
Piedmont Hospital	GA027	0	0	0
ProMedica Flower Hospital	OH012	0	6	6
Puerto Rico Minority Underserved NCORP	PUERTORICO	1	0	1
Reading Hospital	PA107	3	5	8
Rhode Island Hospital	RI005	6	0	6
Riverside Methodist Hospital	OH008	0	0	0
Roswell Park Cancer Institute LAPS	LAPS-NY158	15	6	21
Rush University Medical Center	IL043	9	0	9
Rutgers Cancer Institute of New Jersey	NJ066	9	1	10
Saint Joseph Hospital - Orange	CA087	3	2	5
Saint Joseph's Hospital and Medical Center	AZ009	1	0	1
Saitama Medical University International Medical Center	42061	11	0	11
Sanford NCI Community Oncology Research Program of the North Central Plains	SANFORD	7	8	15
Sarah Cannon Cancer Center	TN047	0	0	0
Saskatoon Cancer Centre	11120	0	0	0
Seoul National University Hospital	43002	2	0	2
Southeast Clinical Oncology Research Consortium NCORP	SCOR	52	0	52

Stanford Cancer Institute Palo Alto	CA141	11	0	11
Stony Brook University Medical Center	NY184	11	18	29
Stroger Hospital of Cook County Minority Underserved NCORP	STROGER	4	1	5
Summa Health System - Akron Campus	OH055	1	11	12
Sun Yat-sen University Cancer Center	60021	3	0	3
Sutter Cancer Research Consortium	SUTTER	9	19	28
The James Graham Brown Cancer Center at University of Louisville	KY002	1	1	2
The Research Institute of the McGill University Health Centre (MUHC)	11318	15	0	15
The US Oncology Network	USONC	1	0	1
Thomas Jefferson University Hospital LAPS	LAPS-PA121	20	5	25
Thompson Cancer Survival Center	TN038	0	0	0
Tibor Rubin VA Medical Center	CA041	0	0	0
Tom Baker Cancer Centre	11134	0	0	0
Trinity Cancer Care Center	ND026	0	5	5
Tulane University School of Medicine	LA001	0	0	0
UC Davis Comprehensive Cancer Center LAPS	LAPS-CA189	16	5	21
UC Irvine Health/Chao Family Comprehensive Cancer Center	CA088	7	1	8
UC San Diego Moores Cancer Center	CA249	6	0	6
UCLA / Jonsson Comprehensive Cancer Center	CA006	17	11	28
UCSF Medical Center-Mount Zion	CA136	6	3	9
UNC Lineberger Comprehensive Cancer Center LAPS	LAPS-NC007	2	5	7
University Health Network-Princess Margaret Hospital	11030	38	1	39
University of Alabama at Birmingham / Deep South Research Consortium LAPS	LAPS-AL002	3	5	8
University of Arkansas for Medical Sciences	AR006	11	1	12
University of Chicago Comprehensive Cancer Center LAPS	LAPS-IL057	15	2	17
University of Cincinnati Cancer Center-UC Medical Center	OH070	4	80	84
University of Colorado Cancer Center LAPS	LAPS-CO070	24	1	25
University of Florida Health Science Center - Gainesville	FL015	2	21	23
University of Illinois	IL040	7	2	9
University of Iowa/Holden Comprehensive Cancer Center	IA018	6	0	6
University of Kansas Cancer Center - MCA Rural MU NCORP	KANSAS	31	0	31
University of Kentucky/Markey Cancer Center	KY010	0	4	4

University of Maryland/Greenebaum Cancer Center	MD015	22	7	29
University of Miami Miller School of Medicine-Sylvester Cancer Center	FL028	7	3	10
University of Michigan Comprehensive Cancer Center LAPS	LAPS-MI014	25	0	25
University of Minnesota/Masonic Cancer Center	MN022	2	0	2
University of Mississippi Medical Center	MS005	0	2	2
University of Nebraska Medical Center	NE003	9	2	11
University of Oklahoma Health Sciences Center LAPS	LAPS-OK003	30	27	57
University of Pennsylvania/Abramson Cancer Center	PA075	4	0	4
University of Rochester LAPS	LAPS-NY167	19	2	21
University of South Alabama Mitchell Cancer Institute	AL068	0	8	8
University of Tennessee - Knoxville	TN021	0	8	8
University of Tennessee Health Science Center	TN030	0	0	0
University of Texas Health Science Center at San Antonio	TX059	2	1	3
University of Texas MD Anderson Cancer Center LAPS	LAPS-TX035	41	2	43
University of Texas Medical Branch	TX045	3	3	6
University of Texas Southwestern Medical Center LAPS	LAPS-TX011	10	5	15
University of Utah - Huntsman Cancer Institute LAPS	LAPS-UT003	13	6	19
University of Vermont and State Agricultural College	VT004	8	4	12
University of Virginia Cancer Center	VA009	9	0	9
University of Wisconsin Carbone Cancer Center LAPS	LAPS-WI020	18	11	29
UPMC Hillman Cancer Center LAPS	LAPS-PA015	67	7	74
Upstate Carolina Consortium Community Oncology Research Program	UPSTATE	11	0	11
USC Norris Comprehensive Cancer Center LAPS	LAPS-CA011	3	5	8
Vanderbilt University - Ingram Cancer Center LAPS	LAPS-TN008	8	1	9
VCU Massey Cancer Center Minority Underserved NCORP	VCU	10	16	26
Veterans Administration Hospital	FL051	0	0	0
Wake Forest University Health Sciences	NC002	2	0	2
Walter Reed National Military Medical Center	MD001	3	0	3

Washington University - Siteman Cancer Center LAPS	LAPS-MO011	37	9	46
Wayne State University - Karmanos Cancer Institute LAPS	LAPS-MI020	21	12	33
WellSpan Health-York Hospital	PA047	12	0	12
West Virginia University Charleston Division	WV004	1	4	5
West Virginia University Healthcare	WV025	2	7	9
Western States Cancer Research NCORP	WESTERN	0	2	2
William Beaumont Hospital-Royal Oak	MI005	9	6	15
Wisconsin NCI Community Oncology Research Program	WINCORP	4	2	6
Women and Infants Hospital	RI012	15	2	17
Women's Cancer Center of Nevada	NV049	15	0	15
Yale University - Yale Cancer Center LAPS	LAPS-CT018	15	7	22
Yonsei University Health System-Severance Hospital	43027	0	0	0

Sponsors & Exhibitors

Platinum Sponsors

The logo for ImmunoGen, featuring the word "immun" in black and "gen" in a bold, black, sans-serif font, with a red dot between them.

ImmunoGen

Antibody-drug conjugates, or ADCs, are a targeted way to treat cancer. For 40 years, ImmunoGen has been researching and developing ADCs designed to disrupt the progression of cancer. Because we believe life deserves fewer interruptions and more good days.



GSK

GSK is a focused, global biopharma company. Our purpose is to unite science, technology and talent to get ahead of disease together and positivity impact the health of billions of people.



MERCK

Merck

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.



Caris Life Science

Caris Life Sciences is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. To learn more, please visit www.CarisLifeSciences.com.



GoPath Diagnostics

GoPath Laboratories is a state-of-the-art CAP-accredited, CLIA-certified molecular diagnostic laboratory providing anatomic pathology, hematopathology, and hereditary cancer testing for clinicians, hospital systems, and pharmaceutical firms. Located just north of Chicago, our laboratory incorporates the latest technologies into our testing platforms including next-generation sequencing, cytogenetics, FISH, IHC, microarray analysis, and ddPCR. We specialize in cancer diagnostics through our OncoTarget NGS-based testing series, which includes solid tumor and liquid biopsy analysis to detect and monitor a cancers genetic mutations.

Sponsors & Exhibitors



Eisai

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate

commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.



AstraZeneca

We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.



IROC

The Imaging and Radiation Oncology Core (IROC) provides integrated radiation oncology and diagnostic imaging quality control programs in support of clinical trials conducted by NRG Oncology and the other Network Groups in the National Clinical Trials Network. IROC staff are here to answer study data submission related radiation therapy and diagnostic Imaging questions from investigators or other research professionals.

Exhibit Hall Schedule:

Thursday 7:00am – 6:00pm

Friday 7:00am – 5:30pm

Saturday 7:00am – 12:30pm

Complimentary coffee, tea, and soft drinks will be served in the exhibit area at specified times on each day that exhibits are open.



Ahead Together

We unite science, technology
and talent to get ahead of
disease together.



Learn more about
a treatment option
from ImmunoGen



**Please see Important Safety Information and full
Prescribing Information, including BOXED WARNING
for ocular toxicity, at [ELAHEREhcp.com](https://www.ELAHEREhcp.com)**

© 2023 ImmunoGen, Inc., All Rights Reserved. US-MIRV-2300197 06/2023
ELAHERE and the ELAHERE logo are trademarks or registered trademarks of ImmunoGen, Inc.
ImmunoGen and the ImmunoGen logos are trademarks or registered trademarks
of ImmunoGen, Inc.

NRG Oncology would like to recognize and thank our commercial supporters for independent medical educational support associated with the NRG Oncology Winter 2024 Meeting.



Eli Lilly and Company

Exact Sciences

Genmab

ImmunoGen Inc.

Novartis

Novocure

Pfizer

Seagen Inc.

Varian

NRG ONCOLOGY SEMIANNUAL MEETING FUTURE DATES & LOCATIONS



Denver, Colorado
July 25-27, 2024



Phoenix, Arizona
January 16-18, 2025



Washington, DC
July 24-26, 2025

#NRG2024